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ABSTRACT 
 
More than 25 years after the discovery of HIV, AIDS still represents a pandemic 
emergency. Antiretroviral therapies are becoming more and more effective, but no 
real cure has yet been found to eradicate it. In order to develop a preventive 
vaccine, the isolation of new immunogens, capable to stimulate humoral immune 
response towards highly conserved viral epitopes, is pivotal.  
In a past work performed by our lab, the fusion between HIV-1 envelope and cell 
membrane was exploited to produce fusion intermediates exposing viral 
conserved epitopes. Such fusion complexes were used to immunize mice to elicit 
antibody production, and to produce hybridomas population expressing antibodies 
against HIV-1. 
During the course of the present work of thesis, hybridoma populations were 
screened for antibody production and neutralization activity. Cells were gradually 
subcloned down to single cell population in order to identify broad-spectrum 
monoclonal antibodies. In order to stabilize antibody expression, and to obtain 
antibodies supernatants close to human antibody, IgG mRNA sequences of the 
selected monoclonal population were cloned to be humanized.  
Viral vectors expressing humanized light and heavy IgG chains were produced by 
matching human constant regions with murine variable regions. Such viral vectors 
were used to co-infect CHO cells in order to obtain a cell line stably expressing 
humanized antibodies. Transgenes integration was confirmed by amplification of 
genomic DNA and humanized antibody production was quantified by ELISA 
assay. 
Obtained results show that viral vectors can integrate transgenes inside target cells 
and, more precisely, that our method works to produce humanized antibodies. 
Moreover, preliminary functional tests show that the produced antibody is 
working. 
Nevertheless, such protocol needs to be devised, as antibody expression remained 
at low concentration values to perform functionality assays. Optimization of this 
method and tests of antibody functionality will allow to the release of a rapid and 
easy protocol to produce cell line stably expressing the antibody of interest. 
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Antibody characterization and analysis could be favored by a stable production 
source.
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RIASSUNTO 
 
A più di 25 anni dalla scoperta del virus HIV, l'AIDS rappresenta ancora 
un'emergenza pandemica. Le terapie antiretrovirali stanno diventando sempre più 
efficaci, ma non è stata ancora trovata una vera cura. Al fine di sviluppare un 
vaccino preventivo, è fondamentale l'isolamento di nuovi immunogeni, in grado 
di stimolare la risposta immunitaria umorale verso epitopi virali altamente 
conservati. 
Nel nostro laboratorio, sono stati prodotti intermedi di fusione che esponessero 
epitopi virali conservati. Tali complessi di fusione sono stati utilizzati per 
immunizzare dei topi in modo da sollecitare la produzione di anticorpi, e per 
produrre ibridomi che esprimessero anticorpi contro HIV-1. 
Nel corso del presente lavoro di tesi, popolazioni di ibridomi sono state sottoposte 
a screening per testare la produzione di anticorpi e l'attività neutralizzante. Le 
cellule sono state subclonate in passaggi successivi fino a popolazioni derivate da 
singola cellula al fine di individuare anticorpi monoclonali ad ampio spettro. Al 
fine di stabilizzare l'espressione degli anticorpi, e di ottenere anticorpi simili ad 
anticorpi umani, le sequenze di mRNA di IgG della popolazione monoclonale 
selezionata sono state clonate per essere umanizzate. 
Vettori virali esprimenti catene umanizzate leggere e pesanti di IgG sono stati 
prodotti clonando le regioni costanti umane in frame con le regioni variabili 
murine. Tali vettori virali sono stati usati per co-infettare cellule CHO in modo da 
ottenere una linea cellulare che esprimesse stabilmente anticorpi umanizzati. 
L’integrazione dei transgeni è stata confermata dall’amplificazione del DNA 
genomico e la produzione di anticorpi umanizzati è stata quantificata mediante 
test ELISA. 
I risultati ottenuti mostrano che i vettori virali sono in grado di integrare i 
transgeni all'interno delle cellule bersaglio e, più precisamente, che il nostro 
metodo funziona per la produzione di anticorpi umanizzati. Inoltre, i 
test preliminari mostrano che l'anticorpo prodotto denota attività interessante. 
Tuttavia, tale protocollo deve essere messo a punto e ottimizzato, in quanto 
l’espressione di anticorpi è su valori di concentrazione troppo bassi per la 
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produzione in larga scala. L’ottimizzazione di questo metodo e dei test di 
funzionalità degli anticorpi permetterà la pubblicazione di un protocollo rapido e 
semplice per produrre linee cellulari che esprimano stabilmente l'anticorpo di 
interesse. La caratterizzazione e l’analisi degli anticorpi sarà quindi favorita da 
una espressione stabile. 
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1. INTRODUCTION 
1.1 HIV-1 discovery, origin and evolution 
In 1981, Gottlieb and colleagues of Los Angeles (California, USA) reported five 
cases of patients affected by pneumonia caused by Pneumocystis carinii and 
associated to heavy immune system deficiencies (Gottlieb et al., 1981). Such 
pathologic condition was considered, to date, extremely rare and usually 
associated to patients already affected by other immunodeficiencies. At the same 
time, more reports rose concerning American homosexual males showing 
pneumocystis associated with Kaposi’s sarcoma, a vascular cancer typically found 
in patients over 60. The disease was characterized by high mortality, mainly due 
to the onset of several other opportunistic infections (Lerner and Tapper, 1984), as 
the one caused by Candida albicans. In the next years a rise of reported cases was 
noticed even in other geographic zones and ethnic groups. Disease transmission 
was proved to be associated with sexual intercourses, exchange of infectious 
blood contaminated syringes and from mother to child during pregnancy: such 
infectious agent was thus transmittable by sex, blood and maternally (Freedman et 
al., 1989). 
Epidemiologic data collected by the Center of Disease Control in Atlanta 
(Georgia, USA), confirmed that this syndrome was an infection previously 
unknown, caused by a viral agent and characterized by strong immune deficiency. 
It was named AIDS, that is, Acquired Immunodeficiency Syndrome (Marx, 1982). 
In 1983, at the Pasteur Institute in Paris, and in 1984 at National Cancer Institute 
in Bethesda (Maryland, USA), AIDS causative agent was isolated from peripheral 
blood of patients. French group directed by Luc Montagnier named it 
Lymphadenopathy Associated Virus (LAV) (Barre-Sinoussi et al., 1983), whereas 
the American team directed by Robert Gallo named it HTLV-III (Popovic et al., 
1984). In 1985, when the viral genome was published, the concurrence of 
retroviral sequences of LAV and HTLV-III was discovered. Afterwards, in 1986, 
the International Committee on Taxonomy of viruses named such viral agent as 
Human Immunodeficiency Virus type 1 (HIV-1). 
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HIV is a genetically related member of the Lentivirus genus of the Retroviridae 
family. Lentiviruses are so called due to the typical chronic course of the disease, 
with a long period of clinical latency, persistent viral replication and involvement 
of the central nervous system. 
The virus is classified, on genome sequence basis, in two types: HIV-1 and HIV-2 
They present a sequence homology higher than 85% and share a large number of 
genes and several studies claim they derived by zoonosis, a transition of a virus of 
primates to humans (Gao et al., 1999). The site of origin was located most likely 
in sub-Saharan Africa, from which the disease spread in USA across the 
Caribbean and later in Europe and in the rest of the world. Indeed, documentation 
is present since the 50s-60s of independent events of transition to humans from 
chimpanzees (Pan troglodytes troglodytes) infected by SIVcpz or, in case of HIV-
2, from collared mangabey (Cercocebus torquatus atys) infected by SIVsm. The 
modality of transition was correlated with hunting and consumption of monkey 
meat, common in some African indigenous populations. After transition to 
humans, HIV-1 accumulated several genetic mutations, mainly due to the activity 
of reverse transcriptase enzyme (lacking a proofreading activity) and to genetic 
recombination events. 
Depending on differences on env gene, four HIV-1 groups were identified: M, N, 
O and P. Group M (Major) is the most common one and it is responsible of 
pandemic. Moreover, it is subdivided into eleven subtypes (clades), from A to K 
(Requejo, 2006), based on the genomic divergence from a common ancestor and 
on the geographical position. Group O (Outlier) is present in Central and West 
Africa and it is responsible for less than 5% of worldwide HIV-1 infections. 
Group N (New, non-M/non-O) was isolated in few individuals in West Africa. 
Group P was discovered only in 2009 (Plantier et al., 2009). HIV-2 is confined in 
the geographic areas containing HIV-1 groups N and O and presents a much more 
limited transmission risk.  
The various groups and subtypes derive by at least seven independent events of 
zoonosis, whereas the whole group M derives by a single transition event (Gao et 
al., 1999). The geographic distribution (figure 1.1) of clades belonging to group 
M seems to resemble the modality of transmission of HIV-1: clade B is mainly 
located  in  Europe   and  North  America,   where  infections  due  to  homosexual  
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Figure 1.1 Schematical representation of HIV-1 subtypes and clades distribution. 
Clade C and A are predominant in Africa, India and South-East Asia whereas Clade B 
is mainly found in America and Europe. (Obtained from 
http://www.pbs.org/wgbh/pages/frontline/aids/atlas/clade.html). 
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relationships and blood contacts (infected needles and transfusions) seems to 
prevail. Clades C, A and E are predominant in Africa, India and South-East Asia 
where transmission occurs mainly mucosally and by heterosexual contacts. 
According to data provided by International AIDS Vaccine Initiative (IAVI), 
clade C covers 48% of global infections, whereas clade A and B cover 
respectively 25% and 16%. 
1.2 Clinical course of HIV infection 
HIV-1 has the ability to infect CD4+! lymphocytes and a variety of other cells in 
the body, including monocytes and thymocytes (Nilsson et al., 2007, Ho Tso Fang 
et al., 2008). The virus enters target cells via cell surface molecules, including 
CD4 and chemokine co-receptors (CXCR4, CCR5) (Berger et al., 1999). During 
the first few weeks of infection, the patient is often affected by a flu-like illness 
and a rash, an illness termed acute HIV-1 infection syndrome (Levy, 2006). This 
initial phase of HIV-1 infection is followed by a gradual deterioration of the 
immune function (figure 1.2). 
 CD4+ cells, also called “T-helper cells,” play a central role in the immune 
response, signaling other cells such as the cytotoxic T cell and the B cells to 
perform their functions (Fahey et al., 1990). Normally, a healthy person has a 
CD4+ count of 800 to 1200 CD4+ T cells per cubic millimeter (mm3) of blood. 
As CD4+ cells are destroyed by HIV and as these cells decrease in number, leaks 
develop in the immune repertoire (Nilsson et al., 2007). Once the CD4+ count 
falls to 500 mm3, half of the immune reserve has been destroyed and minor 
infections including cold sores (herpes simplex), condyloma (warts) and fungal 
infections, thrush and vaginal candidiasis, may occur. These infections are 
troublesome but not life threatening. However, as the CD4+!count falls to!200 
cells/mm3, the patient becomes particularly vulnerable to the serious opportunistic 
infections and cancers characteristic of AIDS, the end stage of HIV-1 disease. 
AIDS is defined as a CD4+!count of !200 cells/mm3, or the presence of a serious 
infection, such as PCP (pneumocystis pneumonia), toxoplasmosis, 
cytomegalovirus  infections  of  the  eye or intestine, as well as debilitating weight  !
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Figure 1.2 Representative graph relating CD4+T-cells with (blue line) with viral load 
(red line) during acute and chronic phase, as well as in full-blown, AIDS when no 
antiretroviral therapy is being used. (Adapted from Immunology, Kuby, Sixth Edition, 
2007) 
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loss, diarrhea, HIV dementia and cancers, Kaposi’s sarcoma and lymphomas 
(Center for Disease Control and Prevention, 1992). 
1.3 HIV-1 structure and genome 
HIV-1 virion (figure 1.3) has a diameter of 100 nm and contains a genome 
constituted by positive polarity single-stranded RNA (ssRNA). The genome is 
present in double copy and enclosed inside an icosahedral protein structure named 
capsid. 
The viral external structure is a phospholypidic bilayer called envelope, derived 
by the cell membrane, and generated during the process of viral budding from 
host cell. Therefore the envelope is constituted both by cell proteins that are 
incorporated during budding (i.e. HLA – Human Leukocyte Antigen – class I and 
II proteins or adhesion proteins) and viral proteins as the gp160. Such complex is 
a heterodimer composed of trimers of the transmembrane gp41 and the external 
surface spanning gp120 glycoproteins, which are strongly glycosylated. Both 
proteins are required for the early phase of infection process, permitting the 
attachment and the fusion of the envelope with the cell membrane. The binding 
between gp120 and gp41 is not covalent and therefore gp120 may be shed 
spontaneously within the local environment and detected in the serum, as well as 
within the lymphatic tissue of HIV- infected patients. 
Anchored to the inside of the envelope, it is present an electron-dense protein 
structure called matrix, mainly constituted by protein p17. The matrix surrounds a 
protein structure called capsid, which is mainly constituted by the viral protein 
p24 and contains the viral genome combined with a nucleoprotein and the 
enzymes Reverse Transcriptase, Integrase and Protease. 
The HIV-1 genome (figure 1.4) encodes the three structural genes gag, pol, and 
env. In addition to these genes, HIV-1 genome presents a complex combination of 
other regulatory/accessory genes. 
The protein-encoding regions are flanked by 5’ and 3’ LTRs (Long Terminal 
Repeats), which consist of 3’ unique element (U3), repeat element (R) and 5’ 
unique element (U5), and harbor some of the cis-acting elements of the genome. 
The cis elements contain signals important for provirus integration into the host 
genome  (ATT repeats, which are located  at the 5’ and 3’ ends of provirus DNA),  
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Figure 1.3 Schematic representation of HIV-1 virion. Viral proteins are shown, located 
on the phospholypidic envelope (gp120, gp41), on the matrix (p17), on the capsid (p24) 
and at core level (protease, integrase, reverse transcriptase) where the genome is 
located. Moreover, cell protein are shown (MHC) as the envelope is derived from cell 
membrane during budding. (Adapted from Immunology, Kuby, Sixth Edition, 2007) !
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enhancer/promoter sequences, transactivation response element (TAR), and 
polyadenylation signal (polyA). Besides the two LTRs there are other cis-acting 
sequences including the primer binding site (PBS); viral RNA packaging/ 
dimerization signals (! and DIS); central polypurine tract (cPPT) and the central 
termination sequence (CTS), leading to the formation, during reverse 
transcription, of a three stranded DNA structure called the central DNA Flap. In 
addition, there is the Rev Responsive Element (RRE) and the purine-rich region 
(polypurine tract; PPT), which provides a second RNA primer for the initiation of 
plus strand DNA synthesis by virus-specific reverse transcriptase 
(Srinivasakumar, 2001; Spirin et al., 2008). Between the LTRs, the provirus 
includes nine open reading frames (ORFs). The gag-pol, gag and env ORFs are 
encoding structural proteins and enzymes that are typical of all retroviruses. 
Additional ORFs encode for essential regulatory proteins (tat and rev genes) and 
accessory proteins (vif, vpu, vpr, and nef genes). There are nineteen protein 
products encoded by the provirus.  
The gag gene encodes the structural proteins of the core (p7, p6), the capsid (p24) 
and the matrix (p17). The pol gene encodes enzymes crucial for viral replication, 
as the reverse transcriptase that converts viral RNA into DNA and has 
ribonuclease H (RNase H) activity (RT; heterodimer p66/p51 and RNase H), the 
integrase (IN; p31) that incorporates the viral DNA provirus into host 
chromosomal DNA and the protease (PR; p11) that cleaves large Gag and Pol 
protein precursors into their components. gag and pol genes are transcribed as a 
whole mRNA, then translated into 160 KDa protein (p160, Gag-Pol precursor), 
which is later cleaved by viral protease. Such cleavage determines the formation 
of Pol proteins and of Gag-precursor (p55), later cleaved into its elements. 
The env gene encodes the glycoproteins in the viral envelope: the surface subunit 
gp120 (SU) and the transmembrane subunit gp41 (TM). They are both trimers 
essential for recognition of cell surface receptors and for entry into target cells. 
Env is translated into an 88 KDa protein that, in Golgi apparatus, undergoes to N-
glycosylation with 25-30 complex residues, raising its molecular weight to 160 
KDa (gp160). Env glycosylation is necessary to gain viral infectivity (Capon and 
Ward, 1991). Gp160 is then cleaved by cell protease furine to form gp120 and 
gp41 (Melikyan, 2008). 
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Figure 1.4 Schematic representation HIV-1 genome. Structural genes (gag, pol, env) are 
represented on the genome and on the virion. Furthermore accessory genes (Rev, Tat, 
Nef, Vif, Vpr and Vpu) are shown on the genome, as well as special sequences like LTR 
(U3-R-U5), PBS (Primer Binding Site), packaging signal !, RRE (Rev Responsive 
Element), PPT (Polypurine tract) and plolyadenilation signal (polyA). (Obtained from 
http://tcf.epfl.ch/page-20833.html). 
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The tat gene encodes for Tat (transactivator, p14), a 14 KDa protein that is 
expressed very early after infection and promotes the expression of HIV-1 genes 
(Perkins et al., 1989). Tat begins its activity by binding the TAR sequence and 
stabilizes the transcriptional elongation process and to increase viral genes 
transcription about 1000-fold. Such increase is achieved by avoiding early 
termination of transcription, thus permitting longer transcripts production. This is 
obtained through Tat association with cellular T-cyclin (Kao et al., 1987; 
Seelamgari et al., 2004; Barboric & Peterlin, 2005; Bolinger & Boris-Lawrie, 
2009; Cheng et al., 2009). 
The Rev protein (regulator of expression of viral proteins, p19), coded by the rev 
gene, ensures the export from nucleus to cytoplasm of the correctly processed 
messenger and genomic RNA, thus enabling the transition from early to late phase 
of HIV-1 genes expression. Rev can bind with high affinity and specificity to a 
highly structured cis-acting RNA element present within the coding region of the 
HIV-1 mRNA called Rev Responsive Element (RRE) (Levin et al., 2009; Malim 
and Cullen, 1991). 
The nef gene encodes a 27 KDa (p27) multifunctional protein with GTPasic 
ability. Its name (Nef) derives from studies indicating its transcription inhibiting 
activity (Negative Factor) (Stumptner-Cuvelette et al., 2001). Moreover, such 
protein can bring to internalization and consequent down regulation of molecules 
present on cell surface as the CD4 receptor (Rhee and Marsh, 1994) and class I 
MHC molecules (except HLA-C and HLA-E) (Cohen et al., 1999), thus 
protecting infected cells from recognition by CD8 cytotoxic lymphocytes (Swigut 
et al., 2004) and from lysis acted by Natural Killer cells (NK). Furthermore, Nef 
is secreted from infected cells to act on B-cells by inhibiting immunoglobulin 
class switch process (Qiao et al., 2006). This way Nef can reduce the production 
of IgG, IgA and IgE, which are necessary counteract against the virus inside the 
organism, especially in mucous membrane and bloodstream (Seelamgari et al., 
2004; Anderson & Hope, 2005; Foster & Garcia, 2008). 
Vpr is 15 KDa protein involved in in the arrest of the cell cycle to promote the 
LTR function. This protein also enables the reverse transcribed DNA to gain 
access to the nucleus in non-dividing cells such as macrophages (Seelamgari et 
al., 2004; Barraud et al., 2008; Oku- mura et al., 2008). 
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Vpu is a protein necessary for the correct release of virus particle, whereas the vif 
gene codes for a small protein (Vif) that enhances the infectiveness of progeny 
virus particles (Seelamgari et al., 2004). 
1.4 HIV-1 replication cycle 
The entry pathway of HIV-1 can be divided into three major events: virus binding 
to the cell, activation and fusion. The viral envelope trimeric complex, composed 
of the heterodimer proteins gp120 and gp41, is essential for virus recognition and 
entry into target cells. Indeed, the gp41 subunit contains a fusogenic hydrophobic 
peptide at its amino terminus, which is essential for fusion of the viral and cellular 
membranes. HIV gp120 binds a 58 kDa monomeric glycoprotein, known as CD4, 
which is expressed on the cell surface of about 60% of circulating T-lymphocytes, 
on T-cell precursors within the bone marrow and thymus, on 
monocytes/macrophages, eosinophils, dendritic cells and microglial cells of the 
central nervous system. The CD4 molecule normally functions as a co-receptor 
for the major histocompatibility complex class II molecule during T-cell 
recognition of a foreign antigen. Upon gp120 binding to the CD4 protein, the 
virus envelope complex undergoes a structural change, exposing a specific 
domain in the gp120 able to bind chemokine receptors on the cell membrane 
(figure 1.5). These molecules are recognized by chemotactic cytokines, as 
chemokines, small proteins that mediate the homing and recruitment of immune 
cells in the course of inflammation. These receptors are classified on the basis of 
the position of disulfide-like cysteine residues, as well as their angiogenic effects. 
Most common co-receptors used by HIV are CXCR4 and CCR5, but other 
potential co-receptors have been described (Alkhatib and Berger, 2007). The "-
chemokine SDF-1 (stromal cell-derived factor 1) is the natural ligand of CXC4, 
whereas CCR5 is a receptor for the #-chemokine family (RANTES, macrophage 
inflammatory proteins MIP-1-" and MIP-1-#). CXCR4 is expressed on many cell 
types, including T-lymphocytes, whereas CCR5 is present on 
monocytes/macrophages, dendritic cells and activated T-lymphocytes. 
The differential expression of chemokine receptors on cell targets has been shown 
to be a major determinant of the HIV-1 tropism (figure 1.6). In fact, there are 
HIV-1  strains  preferentially  binding  the  #-chemokine  receptor  CCR5  present  
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Figure 1.5 Phases of HIV-1 fusion with cell membrane acted by gp120 and gp41. HIV-1 
receptor (CD4) and co-receptors (CCR5 and CXCR4) are also shown. !
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mainly in macrophages and CD4+ T-cells (Coakley et al., 2005). These strains are 
also known as macrophage-tropic (M-tropic) or R5 viruses.  Conversely, other 
isolates use preferentially CXCR4 for entry and replicate in primary CD4+ T-
cells, which also express CXCR4. These strains are known as T-lymphocyte-
tropic (T-tropic) or X4 viruses. Finally, there are HIV-1 isolates that are able to 
bind to both CCR5 and CXCR4 receptors. These strains are termed dual tropic or 
X4R5 viruses. 
In infected patients it is possible to find a heterogeneous viral population with 
different tropism. It is known how some individuals are partially resistant to HIV-
1 infection thanks to a mutation called CCR5-!32, which is named by a deletion 
in the gene coding CCR5 that prevents the receptor exposure on the cell 
membrane. Such mutation is mainly present in Northern Europe people 
(Katzenstein et al., 1997), who result protected even when bearing functional 
CXCR4 molecules (Margolis and Shattock, 2006). In semen both X4 and R5 
tropic viruses are present and they can be transferred during sexual contacts. 
Nevertheless studies reported that transmission is selective for R5 tropic viruses. 
Indeed, sperm cells bear CCR3 and CCR5 on their membrane but not CXCR4 
(Muciaccia et al., 2005) and vaginal cervix epithelial cells rather stop X4 strains 
through mucin (Berlier et al., 2005; Margolis and Shattock., 2006). On the other 
hand it is possible to observe the development of X4 tropic and CD4-indipendent 
variants during late phases of a syndrome caused by an in vivo R5 infection 
(Zehrouni et al., 2004). These variants are strongly virulent and can cause a rapid 
loss of T lymphocytes and an immune system breakdown.  
The double binding of gp120 to both the CD4 and one chemokine receptor allows 
a more stable two-pronged attachment of the virus, which, in turn, allows the N-
terminal hydrophobic portion of gp41 (called fusion peptide) to penetrate the 
target cell membrane. The heptad repeat regions (HR1 and HR2) of gp41 interact, 
causing the collapse of the extracellular portion of gp41 into a hairpin. This loop 
structure brings the virus and cell membranes close together, allowing fusion of 
the membranes and subsequent entry of the viral capsid.  
Following membrane fusion, the virus uncoats into the cytoplasm of the target cell 
freeing the viral RNA (uncoating). The conversion of viral RNA into proviral 
DNA takes place because of the action of the Reverse Transcriptase and the 
Integrase. Through its Ribonuclease H active site, the reverse transcriptase begins  
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Figure 1.6 Receptor and co-receptors of HIV-1 and relative tropisms. CD4 acts as the 
main receptor whereas CCR5 and CXCR4 are co-receptors. CCR5 is mainly express 
on macrophages/monocytes and dendritic cells. CXCR4 is expressed on many cells as 
T-lymphocytes (Berger et al., 1999).  
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the reverse transcription of viral RNA in the cytoplasm that occurs as a minus-
strand polymerization, starting at the primer-binding site, until viral RNA is 
transcribed into a RNA/DNA hybrid double helix. Then, the ribonuclease H site 
breaks down the RNA strand and the polymerase active site of the reverse 
transcriptase completes a complementary DNA strand to form a double helix 
DNA molecule, which is integrated within the cell genome by the viral enzyme 
Integrase. Acting on LTR sequences, this protein cleaves nucleotides of each 3’ 
ends of the double helix DNA, transfers the modified provirus DNA into the cell 
nucleus and facilitates its integration into the host genome. The integration of 
proviral DNA and the expression of the provirus require that target cell is in an 
activated state. Indeed highly transcribed regions, as genes, are preferential 
hotspot for integration (Schröder et al., 2002). Monocytes/macrophages, 
microglial cells, and latently infected quiescent CD4+ T-cells contain integrated 
provirus and are important long-living cellular reservoirs of HIV-1 (Chun et al., 
1997). Upon cell activation, transcription of proviral DNA into a messenger RNA 
occurs. Transcription process initially results in the early synthesis of regulatory 
HIV-1 proteins such as Tat and Rev.  
Viral messenger RNA coding for long fragments migrates into the cytoplasm, 
where structural proteins of new virions are synthesized. The proteins coded by 
pol and gag genes form the nucleus of the maturing HIV particle; the gene 
products coded by the env gene form the glycoprotein spikes of the viral envelope.  
The cleavage of the precursor molecules by the HIV-1 Protease is necessary for 
the generation of infectious viral particles. The formation of new viral particles is 
a stepwise process: two viral RNA strands associate together with replication 
enzymes, while core proteins assemble over them forming the virus capsid. This 
immature particle migrates towards the cell surface. The large precursor 
molecules are then cleaved by the HIV-1 protease, resulting in new infectious 
viral particles, which bud through the host cell membrane, thus acquiring a new 
envelope. During the budding process, the virus lipid membranes may incorporate 
various host cell proteins and become enriched with phospholipids and 
cholesterol. Differently from T-lymphocytes, where budding occurs at the cell 
surface and virions are released into the extracellular space, the budding process  
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Figura 1.7 Simplified design of HIV-1 replication cycle (HIV Web Study – 
www.HIVwebstudy.org) !
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in monocytes and macrophages results in the accumulation of virions within 
intracellular vacuoles, which are then released. 
HIV-1 replication cycle is schematically shown in figure 1.7 
1.5 HIV-1 vaccine: state of the art 
UNAIDS (United Nations programme on HIV/AIDS) estimates that 34 million 
people now live with HIV-1 infection, and 2 million become newly diagnosed 
each year (figure 1.8). Currently available therapy is called HAART (Highly 
Active Antiretroviral Therapy) and, by means of antiretroviral drugs, it can 
suppress viral replication, increasing life expectancy among those infected, but 
cannot cure infection. Several modalities can reduce HIV-1 infection rates in 
persons at risk of exposure, including screening of blood donors, condom usage, 
male circumcision, pre-exposure to chemoprophylaxis and finally, use of vaginal 
gels, like Tenofovir, containing microbicides (Bailey et al., 2007; Grant et al., 
2010; Karim et al., 2010). Although these interventions may reduce susceptibility 
to the virus, in order to limit HIV-1 diffusion a highly efficacious preventive 
vaccine would be desirable. Since 1987, more than 30 candidate HIV-1 vaccines 
were tested on non-human primate models and advanced to human clinical trials 
(Ross et al., 2010). These candidates were based on exploitation of envelope 
proteins (VAX trial) (Pitisuttithum et al., 2006; Flynn et al., 2005), of first 
generation human adenoviral vectors expressing gag, pol and nef genes (STEP 
trial) (Gray et al., 2010), and of vectors, derived from canaripox, coding for clade 
B and E envelope proteins (RV144 trial) (Rerks-Ngarm et al., 2009). 
In particular, STEP trial, did not prove to be effective in limiting HIV-1 infections 
and reducing post-infection viremia. O’Brien et al. (2009) demonstrated that, in 
subjects enlisted in the trial, presence of anti Ad5 antibodies, directed against 
capsid proteins, and against proteins expressed by the genome of used adenoviral 
vector, implies a decreased immunogenicity of the vector and a potential risk of 
increased HIV-1 infection (Buchbinder et al., 2008). RV144 trial resulted, on the 
other hand, partially effective (31%) in reducing infective capacity of HIV-1. 
Even administration of Tat protein to volunteers (Ensoli et al., 2010), seems to 
induce an increase of CD4+ and CD8+ T cells, improving HAART effectiveness,  
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Figure 1.8 A 
Estimated number of 
adults and children 
newly infected with 
HIV, 2008 (Obtained 
from UNAIDS). 
Figure 1.8 B  
Adults and children 
estimated to be 
living with HIV, 
2008 (Obtained from 
UNAIDS). 
 
Figure 1.8 C  
Estimated adult and 
child deaths due to 
AIDS, 2008 
(Obtained from 
UNAIDS). 
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by containment and reduction of viral progression. Nevertheless, to date a 
protective vaccine that could induce both a strong mucosal immunity, block the 
virus on its site of infection, and neutralize antibodies against HIV is still missing, 
and there are many difficulties in generating it. Variability is the main problem, 
allowing the virus to overcome host immunity and the effects of therapeutic 
(drugs) and prophylactic (vaccines) interventions (Menéndez-Arias, 2002). HIV 
variability is a consequence of at least three peculiar features: 1) the “error-prone” 
mechanism of action of the virus enzyme reverse transcriptase, that introduces, on 
average, one substitution per genome per replication round (Sarafianos et al., 
2009); 2) the very rapid viral replication, that generates a high number of virions 
per day (estimated around 1010) in the infected individual (Ho, 1997) and 3) the 
occurrence of recombination processes between two or more different HIV-1 
viruses within the same infected individual. Another major obstacle in HIV-1 
vaccine development is that conserved Env epitopes, capable of stimulating broad 
spectrum neutralizing antibodies, are poorly immunogenic because they are 
masked by carbohydrates, and exposed only transiently during infection phases. 
1.6 Fusion complexes 
In order to obtain broad-spectrum highly neutralizing antibodies against HIV-1, 
which are essential for vaccine production, the study of new immunogens is 
extremely important. In particular, a strong humoral response against viral 
conserved regions would be advisable. 
As already explained, HIV-1 infects host cells by membrane fusion, mediated by 
the envelope glycoproteins gp120/gp41, the CD4 receptor and the co-receptors 
CCR5 and CXCR4. Fusion is triggered during co-receptor binding, when the 
hydrophobic ‘‘fusion peptide’’ region of gp41 is exposed and inserted into the 
membrane of the target cell. The triple-coiled trimeric structure of gp41 exists in 
both the pre-hairpin and the 6-helix bundle configuration (Doms and Moore, 
2000). Both conformations are fusion intermediates. The transition from the pre-
hairpin to the 6-helix bundle configuration may determine the apposition of the 
viral envelope and the cellular membrane (Melikyan et al., 2000) and the mixing 
of the lipid bilayers (Kliger et al., 2000), resulting in the fusion of the 2 
membranes, viral entry into the target cell and initiation of infection. During the 
fusion process, conserved epitopes are exposed that may be necessary for 
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induction of virus neutralizing antibodies. It is known that, while CD4-induced 
conformational changes in the gp120/gp41 occur over a wide temperature range 
(Sullivan et al., 1998), the insertion of the fusion peptide requires a temperature 
higher than 25°C (Doranz et al., 1999). The transition between the pre-hairpin and 
the 6 helix bundle is blocked at 21°C (Melikyan et al., 2000) and the extension of 
the fusion pore does not occur if the temperature is below 31°C (Golding et al., 
2002).  
Our group exploited these features to produce fusion complexes that were used to 
immunize mice and produce neutralizing antibodies (Zipeto et al., 2006). CHO 
cells expressing CD4-CCR5-CXCR4 were co-cultivated with CHO cells 
expressing HIV-1 env gene. Cells co-cultivation at sub-optimal temperatures 
allowed the formation of fusion intermediates that expose conserved epitopes. 
Fusion complexes were ‘‘synchronized’’, using different temperatures and 
different types of fixation, at intermediate conformations on which conserved 
epitopes might be exposed. They were then used to determine which conditions 
resulted in the best induction of HIV-1 neutralizing antibodies. Mice were 
immunized with fusion complexes and later they were sacrificed, and their serum 
was harvested. Antibodies were purified from serum and analyzed for reactivity 
against viral epitopes and for eventual cytotoxic effect against cells. Fusion 
complexes resulted to be immunogenic in mice and reactivity was proved not to 
be due to antibodies directed against cell receptors. 
Additional mice were then immunized with the fixative/temperature combination 
giving the highest neutralizing activity, and using the myeloma cell fusion 
technique, several hybridomas were produced. 
1.7 Immunoglobulins 
Immunoglobulins are a group of globular glycoproteins found in the serum and 
body fluids and play a vital role in the immune response. Since they are capable of 
specifically recognizing and binding to antigens, they are also known as 
antibodies. Immunoglobulins are also found on the surface of B cells where they 
are inserted through the cell membrane (mIg). When B cells are activated by 
antigens, they proliferate and may differentiate into plasma cells, which produce 
and secrete large amounts of antibody. This antibody binds the same antigen as 
the mIg on the B cell from which the plasma cell was derived (i.e. they have the 
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same binding specificity). 
In humans and rodents there are five major classes of immunoglobulin (IgG, IgA, 
IgM, IgE and IgD), which differ from each other in size, charge, amino acid 
sequences and carbohydrate content. Within the classes, there are distinct 
differences (heterogeneity) and subclasses can be distinguished, (e.g. IgG1, IgG2, 
IgG3 and IgG4 in human and IgG1, IgG2a, IgG2b and IgG3 in mice). The number 
of subclasses varies depending on the host species. 
The basic structure of all immunoglobulins consists of two pairs of chains (heavy 
and light, 50-60 kDa and 23 kDa respectively) linked together by, disulphide 
bonds (figure 1.9). The heavy chains dictate the class of immunoglobulin, which 
are µ chains in IgM, " chains in IgG, # chains in IgA, $ chains in IgE and % chains 
in IgD. By contrast, the light chain types are the same for all immunoglobulin 
classes. Each immunoglobulin molecule contains light chains of one of two types, 
either lambda (&) or kappa ('). These chains are antigenically distinct and only 
one type of light chain is present in any single antibody molecule. They are 
usually free of carbohydrate components. The ratio of '/& chains in human 
immunoglobulins is about 60:40, whereas in mouse, rat and rabbit 
immunoglobulins it is about 95:5.  The four-chain structure is seen in IgG, IgD 
and IgE. By contrast, IgA occurs in both monomeric and polymeric forms 
(comprising more than one basic four-chain unit structure) whilst IgM occurs as a 
pentamer with five basic units. Each of the chains comprises a number of globular 
regions (called domains) formed by intra-chain disulphide bonds. At the amino 
terminal of both the heavy and light chains is a single variable region or domain 
(VL or VH) consisting of 110 amino acids; such region is essential for the 
recognition and the binding to antigens. The variable regions of one light chain 
and one heavy chain form one of the antigen-binding sites of the antibody. The 
number of heavy chain constant regions (CH) in an antibody molecule varies; 
being three in IgG, A and D and four in IgM and E. Light chains have only one 
constant region (CL). These regions are called constant because there is very little 
difference in the secondary and tertiary structure of the proteins in these areas. 
There are several genes that code for immunoglobulins and unusually each 
antibody chain molecule is the product of more than one of these. The variable 
region is coded for by a V gene and the constant region by a C", Cµ, C#, C$ or C% 
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gene. 
Individual CH genes are organized such that different exons code for the 
structural domains of the protein. Thus, the C genes contain four exons to code for 
the four constant domains of the µ chain. Each of the C" genes has an additional 
small exon between the first and second CH domain exons that encodes the hinge 
region. The C% gene is organized somewhat differently from the other H chain 
genes in that it contains an extended hinge and lacks a CH2 domain. 
Each antibody class may exist in either a secreted or membrane-bound form. With 
the exception of IgD, the carboxy-terminal sequences of the secreted forms are 
contiguous with the terminal C region domain. By contrast, the unique sequence 
of the membrane-bound forms is encoded by an exon (or exons) downstream of 
the terminal CH exon. This sequence comprises a series of 26 hydrophobic amino 
acids, which spans the plasma membrane and a hydrophilic, cytoplasmic tail 
varying in size from 3 to 28 amino acids. For IgD, the exons for both the secreted 
and membrane-bound forms of the molecule are separated. The production of 
membrane-bound or secreted immunoglobulin is probably regulated at the level of 
RNA processing. 
V region genes code for the variable regions of the antibody. Specific V region 
genes associate with a constant region product of either a heavy chain or a light 
chain, i.e. VH with CH and VL with CL gene products. However, any of the 
products of the CH genes may associate with any of those of the VH genes. 
Kappa chains have V region subgroups differing in the number and position of 
amino acid substitutions and deletions. These molecules share a degree of 
structural  similarity,  which  distinguishes  them  from  lambda  V  or  VH  region 
products. Similar subgroups also exist for lambda and heavy chain V regions. 
All V gene products have regions that are relatively conserved, and it is these that  
define the type of the V gene product (VH or VL) and the subgroup to which it 
belongs. In addition, they have extremely variable zones or ‘‘hot spots’’. These 
are the hypervariable regions, which are involved in the formation of the antigen-
binding site. Light chains have three hypervariable regions whilst heavy chains 
have four. 
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Figure 1.9 Schematic representation of IgG structure (Obtained from!
http://emedicine.medscape.com/article/136897-overview).  
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All immunoglobulins are covalently bonded to carbohydrates in the form of 
simple or complex side-chains. This carbohydrate may assist in secretion of the 
antibody by plasma cells and may affect the biological functions of the molecule, 
which are associated with the constant regions of the heavy chains. Relying on 
enzymatic digestions acted either by papain or pepsin, in immunoglobulins it is 
possible to distinguish two functional domains: the Fab fragment (Fragment 
antigen binding), where the antigen specificity of the molecule resides, consists of 
the two VH–CH1 domains and the two VL–CL domains; the Fc fragment 
(Fragment crystallizable) consists of the CH2 and CH3 domains (and CH4 in IgM 
and IgE) of both heavy chains (figure 1.9). The hinge region binds these two 
fragments. As its name suggests, this area allows slight relative motion between 
the two fragments. This mobility is important in antigen binding. The hinge 
region contains a high number of proline and cysteine residues; the latter form 
inter-chain disulphide bonds, which maintain the integrity of the molecule. These 
bonds also prevent folding in this area making it especially vulnerable to 
enzymatic cleavage. The number of these disulphide bonds varies between classes 
and subclasses of antibody (Bengten et al., 2000). 
1.7.1 Immunoglobulin G 
IgG  (figure 1.9) comprises 70–75% of the circulating immunoglobulins. IgG has 
a molecular weight of 146 kDa, it is the major immunoglobulin produced during a 
secondary immune response and is the only antibody with antitoxin activity. As 
already said, both humans and mice produce four subclasses of IgG. These 
molecules vary in molecular weight, the number and position of inter-chain 
disulphide bonds and in some functional properties. Many cells (including 
monocytes/macrophages, B cells, NK cells and some T cells) bear molecules on 
their surface, which bind IgG through the Fc region. These are known as Fc 
receptors. Fc receptors on macrophages, some T cells and killer cells allow these 
cells to bind antibodies attached to specific antigens on cells (target cells) and can 
lyse these target cells through a mechanism known as antibody-dependent cellular 
cytotoxicity (ADCC). IgGs are also found in mucous membrane secretions and 
therefore have a role in immunity to infection at mucosal surfaces (Bengten et al., 
2000). 
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1.8 Lentiviral Vectors 
Viral vectors have gained their popularity in basic research and gene therapy 
applications because of their high rates of gene transfer, that are far superior to 
those achieved with non-viral methods. Numerous types of virus-derived gene 
transfer systems are available to date. These genetic vehicles are based either on 
DNA viruses or on RNA viruses. The corresponding vectors either integrate into 
the host genome or express their genetic information episomally. Retroviral 
vectors, due to their ability to integrate into the host DNA, are widely used in both 
cell biology and biomedicine. Retrovirus-based systems (Buchschacher, 2001), 
unlike episomal viruses (herpes simplex virus — HSV, adenovirus), offer stable 
and long-term transgene expression. A serious drawback of using retroviral 
vectors in clinical trials is their natural disposition to integrate near promoters and 
regulatory regions (Wu et al., 2003; De Palma et al., 2005; Tsukahara et al., 2006; 
Deichmann et al., 2007; Daniel & Smith, 2008) and to induce insertional tumors 
due to the presence of potent transcriptional enhancers in viral long terminal 
repeats (LTRs). Other limitations to the application of retroviral vectors are their 
ability to insert only relatively small expression cassettes and their low production 
titer. Moreover they can infect only dividing cells. This is because viral 
preintegration complex (PIC), a large nucleoprotein complex responsible for viral 
cDNA integration, cannot enter the cell nucleus and requires disassembly of the 
nuclear envelope during mitosis (Roe et al., 1993; Lewis & Emerman, 1994). 
Some of these drawbacks can be avoided by using lentiviral vectors. Lentiviruses 
have evolved different strategies to interact with the host cell chromatin and do 
not integrate preferentially into close proximity of transcription start sites but 
rather favor introns in chromosomal regions rich in expressed genes (Schroder et 
al., 2002; Mitchell et al., 2004; De Palma et al., 2005; Laufs et al., 2006; Yang et 
al., 2008a; Felice et al., 2009; Wang et al., 2009). Other advantages of lentivirus-
based vectors, important for research and gene therapy applications, are their 
ability to infect both dividing and non-dividing cells, relatively large cargo 
capacity (7–8 kb without affecting vector titer) and target specificity achieved by 
pseudotyping. These features make lentiviral vectors promising agents in research 
and medicine. Consistently with this information, a HIV-1 based lentiviral vector 
is an optimal solution to integrate the transgenes of interest. Nevertheless, when 
using HIV-1-based vector it is imperative to develop a vector-production system 
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that minimizes the risk of reconstituting a replication-competent lentivirus (RCL). 
First-generation lentiviral vectors were produced by transient co-transfection of 
the packaging plasmid, which also contained the transgene, and of the envelope 
plasmid; therefore a single recombination event could determine the formation of 
a RCL. For this reason the viral genome was split into multiple fragments to 
minimize the potential formation of replication-competent viruses; hence, second- 
and third-generation lentiviral vectors were developed. Second-generation 
lentiviral vectors need transient co-transfection of plasmids separately expressing 
the transfer vector genome, the viral structural components (Gag, Pol and Rev), 
and a heterologous envelope protein. Each of these components have undergone 
several refinements in recent years, with due emphasis being put on developing 
vector systems capable of producing high titer supernatants, but also having 
improved biosafety profiles. Indeed, in third-generation vectors, the structural 
components are divided in two constructs expressing Gag-Pol (the former) and 
Rev (the latter) and are both co-transfected with the envelope plasmid and the 
transfer vector. 
In both second- and third-generation vectors, the transfer (integrating) vector 
contains two main regions that express the viral RNA genome following 
transfection during vector production: 1) a multiple cloning site for the insertion 
of various expression cassettes and 2) flanking long-terminal repeats (LTRs) that 
have several distinct functions. First, the 5’-LTR can act like an RNA pol II 
promoter. Second, the 3’-LTR acts to terminate transcription and promote 
polyadenylation. Third, the LTR has recognition sequences necessary for 
integration into the genome. Moreover the vector presents important cis-acting 
DNA elements, as the central polypurine tract sequence (cPPT) and, eventually 
the woodchuck post-regulatory element (WPRE), which enhance the transduction 
efficiency and transcript stability, respectively (Follenzi et al., 2000; Park and 
Kay, 2000; Zufferey et al., 2004; Zennou et al., 2000). The cPPT is a small DNA 
fragment found in the pol gene of HIV that is usually cloned 5’ to the internal 
promoter region, whereas the WPRE is cloned 3’ to the inserted transgene so that 
it is in close proximity to the poly(A) signal in the 3’-LTR. An important feature 
in the third-generation lentiviral transfer plasmid is a 400-bp deletion in the U3 
region of the 3’-LTR, which debilitates the 5’-LTR RNA pol II promoter activity 
following integration (Park and Kay, 2000; Zufferey et al., 1998). Since this 
                                                                                                                Introduction 
 
! #'!
deletion renders the LTR largely transcriptionally inactive (Zufferey et al., 1998), 
it also provides important features to SIN vectors: the vector has a decreased 
chance of insertional mutagenesis due to transcription from the 3$ LTR of the 
integrated provirus; the lentiviral vector becomes Tat-indipendent. This is a 
particular advantage as Tat expression is toxic for cells. 
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2. AIM OF THE WORK 
This work is focused on the stabilization of the production of broad-spectrum 
neutralizing antibodies against HIV-1. Mice were immunized with fusion 
complexes obtained by co-cultivation of cells expressing HIV-1 envelope proteins 
(gp120-gp41) with cells expressing receptors used by the virus to enter host cells 
(CD4-CXCR4-CCR5). Cell membranes fusion was blocked using non-permissive 
temperatures and various fixatives. Mice sera were analyzed for IgG 
concentration. Fusion complexes demonstrated to be strong immunogenic agents 
and were used for immunization of additional mice. Mice spleen cells were used 
to produce hybridomas in combination with myeloma cell line X63.Ag8.653 
(mouse myeloma).  
This work can be divided into two parts: 
1) Isolation and of new neutralizing antibodies directed against HIV-1 
2) Production of viral vectors expressing humanized light and heavy chains 
of IgG, and use of such vectors to obtain a cell line stably expressing 
humanized IgG. 
Starting from hybridoma supernatants the aim of the work was to identify broad-
spectrum neutralizing antibodies against HIV-1 and to stabilize their expression. 
An additional objective was to humanize such antibodies in order to have a better 
relation with control antibodies (Tri-Mab) used for neutralization assays, and to 
use them for possible therapeutic purposes. In order to do this, human IgG 
constant regions (heavy and light) were cloned into two different viral vectors, in 
which later murine variable regions, obtained from mentioned mice hybridomas, 
were added. Such vectors were used to transduce CHO cells, which were then 
cloned to single cell populations in order to obtain a cell line stably expressing 
humanized IgG. The functionality of the produced antibody was then tested. 
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3. MATERIALS AND METHODS 
3.1 Eukaryotic Cell lines  
The TZM-bl cell line consists of engineered HeLa cells expressing the HIV-1 
receptors (CD4, CXCR4, CCR5) and two different reporter genes coding for 
Photinus pyralys luciferase enzyme (luc gene) and for beta-galactosidase (LacZ 
gene), both placed under control of HIV-1 LTR. These cells are maintained under 
selective conditions (G418, final concentration 50 µg/ml) in complete  Dulbecco’s 
Modified Eagle Medium (DMEM - 50% Fetal Bovine Serum, 1% glutamine, 1% 
penicillin/streptomycin). Variants of such cell line (TZM-bl Fc%RI and TZM-bl 
Fc%RIIb) were also used. 
CHO is a cell line derived from the ovary of an adult Chinese hamster 
(Cricetulus griseus). CHO cells are used in studies of genetics, toxicity screening, 
nutrition and gene expression, particularly to express recombinant proteins. 
Today, CHO cells are the most commonly used mammalian hosts for industrial 
production of recombinant proteins. 
293T/17 cells derive from HEK-293 (Human Embryonic Kidney) and 
constitutively express the simian virus 40 (SV40) large T antigen. They are used 
to produce retroviruses, pseudoviruses and viral vectors. 
3T3 cells come from a cell line established in 1962 at the Department of 
Pathology in the New York University School of Medicine. The 3T3 cell line has 
become the standard fibroblast cell line but it was originally obtained from Swiss 
mouse embryo tissue. 
3.2 Pseudovirus production 
3.2.1 Transfection of 293T/17 cells 
3 x 106 293T/17 cells were seeded in a 100 mm dish containing 10 ml of complete 
DMEM (FBS 10%, Penicillin-streptomycin 5%, Glutamine 5%) and incubated 
overnight to show a monolayer confluence of about 50-80% on transfection day. 
In a sterile tube, 1,5 µg of Env plasmid DNA and 3 µg of backbone plasmid DNA 
(pSG&env) were added to the appropriate volume of pure DMEM (serum-free), so 
that the total volume of the mixture were 33,5 µl. Into a second sterile tube, 201,3 
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µl of pure DMEM were mixed with 16 µl of FuGENE 6 reagent (Roche). The 
entire content of the plasmid DNA mixture from the first tube was transferred to 
the second tube containing the FuGENE solution, mixed by pipetting and 
incubated 30 minutes at room temperature to allow the complex formation. The 
entire amount of transfection complexes was added to 293T/17 cells, seeded the 
day before. The cells were incubated for about 5 hours at 37°C in a 5% CO2 
incubator to allow the entrance of the plasmids into the cells; later the medium 
containing DNA-FuGENE complexes was decanted and replaced with 5 ml of 
fresh complete DMEM. The transfected cells were incubated at 37°C, 5% CO2 for 
48 hours. The culture supernatant containing pseudovirus was harvested and the 
FBS concentration in the virus-containing culture medium was adjust to 20%. It 
was then filtered through a 0.45-µm filter, distributed into aliquots of appropriate 
volume and stored at -80°C. 
3.2.2 Pseudovirus titration (TCID50 Assay) 
A volume of 100 µl of grow medium per well was placed in all wells of a 96-well 
flat-bottom culture plate. An amount of 25 µl of pseudovirus was placed into the 
first 4 wells of the first column and mixed; 5-fold serial dilutions were performed 
by transfer of 25 µl from each well to the next one, for a total of eleven dilutions. 
From the 11th dilution, 25 µl were discarded. Wells in column 12 served as cell 
controls (no virus added). A volume of 100 µl of TZM-bl cells (10.000 cells/100 
µl DMEM containing 25 µg DEAE dextran/ml) was added to all wells, to obtain a 
DEAE-Dextran final concentration of 10 µg/ml. The cells and pseudovirus were 
incubated at 37°C, 5% CO2 for 48 hours. 
A volume of 100 µl of culture medium was removed from each well, leaving 
approximately 100 µl. Steadylite Plus Reagent (100 µl) (Perkin Elmer) was 
dispensed to each well and incubated at room temperature for 2 minutes to allow 
complete cell lysis. The solution was mixed with the cells and 150 µl were 
transferred to a corresponding 96-well black plate to read the plate in a 
luminometer (Victor3 – Perkin Elmer – 482 nm). The TCID was calculated using 
the Montefiori’s TCID50 macro. 
 (http://www.hiv.lanl.gov/content/nab-reference-strains/html/home.htm) 
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3.3 Neutralization assay 
A volume of 150 µl of growth medium was placed in all wells of column 1 of a 
96-well flat-bottom culture plate. This column was used as cell control. Aliquots 
of 100 µl of growth medium were placed in all wells of column 2 (column 2 will 
be the virus control) and 40 µl were added in all wells of columns 3-12. A volume 
of 11 µl of test samples was added to each well in column 3 and 4 of row H. To 
test other samples, 11 µl of each sample were added to each well in columns 5 and 
6, 7 and 8, 9 and 10, 11 and 12 of row H.  
The samples were mixed in row H and 50 µl were transferred to row G. The 
transfer was repeated serially, diluting samples through the columns to row A 
(these are serial 3-fold dilutions). After final transfer and mixing were completed, 
50 µl were discarded from the wells in columns 3-12, row A. 
A vial containing the pseudovirus preparation was thawed in a room temperature 
water bath and the pseudovirus was diluted in grow medium to achieve a 
concentration of 2000 TCID50/ml. A volume 50 µl of cell-free virus (100 
TCID50) was dispensed to all wells in columns 2-12, rows A through H. The 
plate was incubated at 37°C, 5% CO2 for 1 hour. 
A suspension of TZM-bl cells, at a density of 1 x 105 cells/ml in growth medium, 
containing DEAE dextran (37.5 µg/ml) was prepared. A volume of 100 µl of cell 
suspension (10000 cells per well) was dispensed to each well in columns 1-12, 
rows A through H, to obtain a DEAE dextran final concentration of 15 µg/ml. The 
plate was incubated at 37°C, 5% CO2 for 48 hours. 
Part of culture medium (150 µl) was removed from each well, leaving 
approximately 100 µl. A volume 100 µl of Steadylite Plus Reagent (Perkin Elmer) 
was dispensed to each well and incubated at room temperature for 2 minutes to 
allow complete cell lysis. After mixing, 150 µl of solution were transferred to a 
corresponding 96-well black plate and read in a luminometer (Victor3 – Perkin 
Elmer – 482 nm). 
The neutralization percentage was determined according to following formula: 
1! RLU(cells+serum  sample+viruus) ! RLU(cells  only)RLU(cell+virus) ! RLU(cells  only)
"
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3.4 Concentration of antibody supernatants 
When necessary, supernatants of antibody producing clones were 
concentrated using centrifugal filter units (Amicon Ultra 50 kDa 15 ml – 
Millipore). Supernatants were centrifuged 30 minutes at 4000 g. 
3.5 Production of cells expressing humanized IgG 
3.5.1 Lentiviral Vectors Production 
5 x 106 293T/17 cells were seeded in a 10 cm dish, approximately 24-30 hours 
before transfection and incubated at 37°C, 5% CO2.  
The plasmid DNA mix was prepared by adding 3 µg ENV plasmid, 5 µg 
Packaging plasmid (pMDLg/p RRE or CMV R8.74), 2,5 µg of pRSV-REV and 
10 -15 µg of either pTY2-CMV-humanized_IgG-IRES-PURO-WPRE or pTY2-
CMV-humanized_IgK-IRES-NEO together. The plasmid solution was made up to 
a final volume of 450µl with 0,1 XTE/dH2O (2:1). Finally 50 µl of 2,5M CaCl2 
was added and the solution was incubated 5 minutes at RT. 
The precipitate was formed by dropwise addition of 500 µl of a 2x HBS solution 
to the 500 µl DNA-TE-CaCl2 mixture while vortexing at full speed. The 
precipitate was added to the 293T/17 cells immediately following the addition of 
the 2X HBS. The CaP-precipitated plasmid DNA was allowed to stay on the cells 
for 14-16 hours, after which the medium was replaced with fresh medium for 
virus collection to begin. 
The cell supernatant was collected 24 hours after change of medium, filtered 
through a 0,45- µm filter and distributed into aliquots of appropriate volume and 
stored at -80°C. 
3.5.2 Cells co-transduction 
5 x 106 CHO cells were seeded in a 10 cm dish, approximately 24-30 hours before 
transduction and incubated at 37°C, 5% CO2. A volume of 200 µl of both freshly 
prepared viral vectors (expressing humanized light and heavy chains) was added 
to cell medium. After 48 hours from co-infection cells were placed under selective 
conditions by adding neomycin (100 µg/ml) and puromycin (5 µg/ml). After one 
week of selective conditions the protocol proceeded to single cell cloning. 
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3.6 ELISA Assays 
IgG concentration of hybridomas supernatants was detected using Mouse-IgG 
Elisa Kit (Roche). IgG concentration of supernatants of humanized IgG producing 
CHO cells was detected with Human IgG FastELISA Kit (RD Biotech). Both 
assays were performed following manufacturer’s instructions. 
3.6.1 ELISA on whole cells 
An amount of 5x104 3T3.T4.CCR5 cells was seeded in complete DMEM in a 96 
well flat-bottom culture plate approximately 24 hours before the assay and 
incubated at 37°C, 5% CO2. Cells were washed three times in PBS without 
calcium and magnesium and fixed with 0,2% PFA, O/N at 4°C. After PBS wash, 
cells were treated 10 minutes at room temperature with glycine 100 mM pH 7 
(100 'l/well) and washed again. Cells were blocked in PBS milk 4% for 2 hours 
at 37°C and washed twice with PBS-tween 20 0,1%. Antibodies from mouse sera 
were diluted in PBS-BSA 2% and 50 'l of samples were added in duplicate in 
each wells and incubated 90 minutes at room temperature. After three washes 
with PBS tween 20 0,1%, a 1:3000 dilution in 1% BSA of a goat-anti-mouse 
horse radish peroxidase conjugated antibody (Dako, Denmark) was incubated for 
60 min at room temperature, plates were washed with T-PBS and developed using 
the Sigma Fast OPD Peroxidase Substrate (Sigma). The developed color was read 
at OD490. 
3.7 Nucleic acids extractions from eukaryotic cells 
3.7.1 Genomic DNA extraction 
An amount of 1 x 106 CHO cells was seeded in a 60 mm dish, approximately 24-
30 hours before extraction and incubated at 37°C, 5% CO2. A suspension of 
trypsinized cells was prepared and 750 'l of Lysis Buffer and 30 'l Proteinase K 
were added. The cells were incubated overnight at 55°C with gentle shaking. A 
spin of 8 minutes at 4°C was performed and the supernatant was collected into a 
clean tube. A volume of 250 'l of saturated NaCl (~6M) was added and the 
solution was mixed by inversion to precipitate the proteins. The sample was 
centrifuged at max speed in a microcentrifuge (~12600 g) for 10 minutes at 4°C to 
spin down the proteins. The supernatant was collected into a clean tube, avoiding 
transfer of the white precipitate. A volume of 500 'l of isopropanol was added 
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and the solution was mixed by inversion until a white thready material was 
visible. A max speed centrifuge (~12600 g) of 10 minutes at 4°C was carried out 
and the pellet was washed with 70% EtOH (100-800 'l). The genomic DNA was 
air-dried for 45-60 minutes and dissolved in 100'l H2O containing RNase. OD260 
or OD260/280 was measured to determinate the genomic DNA concentration. 
3.7.2 RNA extraction and RT-PCR  
Templates for human constant and murine variable IgG regions were obtained 
from human PBMC and from clones isolated from hybridomas. Total RNA was 
extracted from cells using miRNeasy mini kit with RNase-free DNase set 
(Qiagen) following manufacturer’s instructions. RNA concentration was 
measured using a spectrophotometer (Nanodrop). GoScript RT kit (Promega) was 
used to reverse transcribe total RNA to cDNA with random primers. 
Manufacturer’s instructions were followed using samples of 4 µg RNA. 
3.8 Bacterial protocols 
3.8.1 Bacterial transformation  
Calcium chloride competent Top10 cells (E. coli) were thaw on ice for 5 minutes. 
50 µg of circular DNA was added to cells and gently stir with tip. The cells were 
incubated on ice for 30 minutes to thaw competent cells. The heat shock was 
obtained putting the tube with DNA into water bath at 42°C for 20 seconds. The 
tube was put back on ice for 2 minutes to reduce damage to the cells. One ml of 
LB medium (with no antibiotic added) was added to the cells and incubated for 1 
hour at 37°C. Cells were harvested at 5000 rpm for 5 minutes and about 100-150 
µl of the resulting culture was spread on warmed LB plates (with the appropriate 
antibiotic added – usually Ampicillin or Kanamycin). The transformed cells were 
grown overnight at 37°C. For TA-cloning protocol (Invitrogen), provided 
MachT1 cells were used. 
3.8.2 Plasmid DNA extraction from bacterial cells 
Midipreps were performed using Qiagen Plasmid Midi Kit. 
Bacterial culture was harvested after 12–16 h of growth by centrifuging at 6000 g 
for 15 min at 4°C. The pellet was completely resuspended in 4 ml Buffer P1. A 
volume of 4 ml Buffer P2 was added, mixed by inverting the sealed tube 4–6 
times, and incubated at room temperature (15–25°C) for 5 min. During the 
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incubation, the cap was screwed onto the outlet nozzle of the QIAfilter Cartridge, 
and placed in a convenient tube. A volume of 4 ml pre-chilled Buffer P3 was 
added to the lysate, and mixed immediately and thoroughly by inverting 4–6 
times. The lysate was poured into the barrel of the QIAfilter Cartridge and 
incubated at room temperature for 10 min. The QIAGEN-tip was equilibrated by 
applying 4 ml Buffer QBT, and the column was allowed to empty by gravity flow. 
The cap was removed from the QIAfilter Cartridge outlet nozzle. The plunger was 
inserted into the QIAfilter Cartridge, and the cell lysate was filtered into the 
equilibrated QIAGEN-tip. The lysate was allowed to enter the resin by gravity 
flow. The QIAGEN-tip was washed with 2 x 10 ml Buffer QC. DNA was eluted 
with 5 ml Buffer QF. DNA was precipitated by adding 3.5 ml room-temperature 
isopropanol, mixed, and centrifuged at 15000 g for 30 min at 4°C. The 
supernatant was decanted. The DNA pellet was washed with 2 ml of room 
temperature 70% ethanol and centrifuged at 15000 g for 10 min. The supernatant 
was decanted. The pellet was air-dried for 5–10 min and DNA was redissolved in 
a suitable volume of H2O. 
3.9 PCR amplification 
Reagents for PCR were purchased from 5 Prime. Primers were synthetized by 
Invitrogen.  
3.9.1 Primers for human IgG constant regions 
Reverse primers for amplification of human constant regions (heavy and light) 
were designed by modification of primers described by Dr. Gary McLean 
(McLean et al., 2000): in particular, restriction sites were changed from XhoI to 
SalI (light chain) and from HindIII to HpaI to clone the amplified sequences in 
our vectors. Forward primers were designed from scratch (Table 3.1).  
3.9.2 Primers for murine IgG variable regions 
Forward primers for murine variable regions were based on Mouse-Ig Primer set 
(Novagen) changing restriction site to AgeI (light chain) and NheI (heavy chain), 
whereas reverse primers were made to match the frame of human constant 
regions.  
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light chain - IgK
Primer Sequence Tm
HuIgKcF ATATATACCGGTTTCATCTTCCCGCCA 59.4°C
HuIgKcR ATATATATGTCGACTCAACACTCTCCCCTGT 59.6°C
heavy chain - IgG
Primer Sequence Tm
HuIgGcF ATATATAGCTAGCTCGGTCTTCCCCCTGG 61.8°C
HuIgGcR ATCCACATGTTAACTCATTCACCCGGAGACA 62.3°C
Table 3.1 Primer for amplification of human IgG constant regions 
Group Primer Sequence Tm
group A MuIgKvFA GGACCGGTATGRAGWCACAKWCYCAGGTCTTT 62-66.3°C
group B MuIgKvFB GGACCGGTATGGAGACAGACACACTCCTGCTAT 65.6ºC
group C MuIgKvFC ACTAACCGGTATGGAGWCAGACACACTSCTGYTATGGGT 66.3-67.7°C
group D MuIgKvFD1 ACTAACCGGTATGAGGRCCCCTGCTCAGWTTYTTGGIWTCTT 67.2-69.5°C
MuIgKvFD2 ACTAACCGGTATGGGCWTCAAGATGRAGTCACAKWYYCWGG 64.5-68.5°C
MuIgKvFE1 ACTAACCGGTATGAGTGTGCYCACTCAGGTCCTGGSGTT 68.8-70.3°C
group E MuIgKvFE2 ACTAACCGGTATGTGGGGAYCGKTTTYAMMCTTTTCAATTG 62.4-67.3°C
MuIgKvFE3 ACTAACCGGTATGGAAGCCCCAGCTCAGCTTCTCTTCC 68.4°C
MuIgKvFF1 ACTAACCGGTATGAGIMMKTCIMTTCAITTCYTGGG 63-69.1°C
group F MuIgKvFF2 ACTAACCGGTATGAKGTHCYCIGCTCAGYTYCTIRG 63.7-71.3°C
MuIgKvFF3 ACTAACCGGTATGGTRTCCWCASCTCAGTTCCTTG 63.8-65.8°C
MuIgKvFF4 ACTAACCGGTATGTATATATGTTTGTTGTCTATTTCT 57.5°C
MuIgKvFG1 ACTAACCGGTATGAAGTTGCCTGTTAGGCTGTTGGTGCT 67.4°C
group G MuIgKvFG2 ACTAACCGGTATGGATTTWCARGTGCAGATTWTCAGCTT 62.6-64.3°C
MuIgKvFG3 ACTAACCGGTATGGTYCTYATVTCCTTGCTGTTCTGG 62.7-66.4°C
MuIgKvFG4 ACTAACCGGTATGGTYCTYATVTTRCTGCTGCTATGG 61.3-66.7°C
reverse MuIgKvR ATATACCGGTTACAGTTGGTGCAGCATCAGCCCG 66.5°C
Table 3.2 Primer for amplifications of light chain variable regions of murine IgG 
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Group Primer Sequence Tm
group A MuIgHFA GGGCTAGCATGRASTTSKGGYTMARCTKGRTTT 60.4-70°C
group B MuIgHFB GGGCTAGCATGRAA TGSASCTGGGTYWTYCTCTT 63.7-68°C
MuIgHFC1 ACTAGCTAGCATGGACTCCAGGCTCAATTTAGTTTTCCT 64.6°C
group C MuIgHFC2 ACTAGCTAGCATGGCTGTCYTRGBGCTGYTCYTCTG 64.2-70.5°C
MuIgHFC3 ACTAGCTAGCATGGVTTGGSTGTGGAMCTTGCYATTCCT 65.9-69.8°C
MuIgHFD1 ACTAGCTAGCATGAAATGCAGCTGGRTYATSTTCTT 61.8-64.7°C
group D MuIgHFD2 ACTAGCTAGCATGGRCAGRCTTACWTYYTCATTCCT 61.4-66.4°C
MuIgHFD3 ACTAGCTAGCATGATGGTGTTAAGTCTTCTGTACCT 62.2°C
MuIgHFE1 ACTAGCTAGCATGGGATGGAGCTRTATCATSYTCTT 62-65°C
group E MuIgHFE2 ACTAGCTAGCATGAAGWTGTGGBTRAACTGGRT 60.5-64.9°C
MuIgHFE3 ACTAGCTAGCATGGRATGGASCKKIRTCTTTMTCT 61.3-67.7°C
MuIgHFF1 ACTAGCTAGCATGAACTTYGGGYTSAGMTTGRTTT 61-66°C
group F MuIgHFF2 ACTAGCTAGCATGTACTTGGGACTGAGCTGTGTAT 63.6°C
MuIgHFF3 ACTAGCTAGCATGAGAGTGCTGATTCTTTTGTG 61.1°C
MuIgHFF4 ACTAGCTAGCATGGATTTTGGGCTGATTTTTTTTATTG 60.7°C
HuIgG1R ATATAGCTAGCTGGGGGTGTCGTTTTGGCG 64.7ºC
reverse HuIgG2aR ATATAGCTAGCTGGGGCTGTTGTTTTGGCT 63.1ºC
HuIgG2bR ATATAGCTAGCGTGGGGTGTTGTTTTGGCT 63.1ºC
Table 3.3 Primer for amplification of heavy chain variable regions of murine IgG 
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A total of 15 degenerated forward primers for mouse light chain were used. They 
were divided into 7 groups (A-G) as indicated by the manufacturer. One reverse 
primer was designed (details in Table 3.2). 
Fifteen degenerated forward primers for mouse heavy chain were used. They were 
divided into 6 groups (A-F) as indicated by the manufacturer. Three reverse 
primers (IgG1, IgG2a, IgG2b) were designed (details in Table 3.3). 
3.9.3 PCR reactions 
All PCR were performed considering a final volume of 50 µl; dNTPs final 
concentration was 200 µM; a total amount of 10 pmoles for each primer was used. 
Concerning primer pools, the final amount was calculated as the sum of all 
primers of the pool. 
PCR to amplify constant regions consisted in an initial denaturation at 94°C for 4 
minutes, 40 cycles divided in 30 seconds denaturation (94°C), 30 seconds 
annealing (58°C) and 1 or 2 minutes elongation (72°C) for light or heavy chain 
respectively, plus 10 minutes of final elongation.  
All PCR reactions for variable regions were performed with an initial denaturation 
of 94°C for 4 minutes, 40 cycles consisting of 30 seconds denaturation (94°C), 30 
seconds annealing (58°C) and 1 minute elongation (72°C).  
PCR to reveal humanized IgGs were performed using forward primer of mouse 
variable regions and reverse primers of human constant regions. For both heavy 
and light chains, 35 cycles were used, consisting in 30 seconds denaturation 
(94°C), 30 seconds annealing (58°C) and 2 minutes elongation (72°C). 
3.10 Vectors 
Vectors pTY2-CMV-GFP-IRES-NEO (Neo) (10040 bp) and pTY2-CMV-IRES-
PURO-WPRE (Puro) (10021 bp) were kindly provided by Dr. Andrea Cara (ISS – 
Rome, Italy), and were used to clone IgG light and heavy chain respectively. They 
both contain a CMV promoter, after which it is possible to insert a transgene (Neo 
bears the sequence for GFP), followed by an IRES region. Downstream this 
sequence the vectors present a gene for antibiotic resistance (Neomycin on Neo 
and Puromycin on Puro). Vector Puro presents an additional sequence (WPRE) 
that enhances transgenes expression.  Defective LTR (!U3) sequences are present 
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in both vectors at the extremities of the coding sequences (upstream CMV and 
downstream Neomycin or WPRE sequence). 
3.11 Cloning IgG regions 
Reagents were purchased from Invitrogen (TOPO TA Cloning Kit), Promega (T4 
Ligase) New England Biolabs (endonucleases) and Qiagen (Plasmid MIDI kit). 
Fresh PCR products (human constant regions and mouse variable regions of IgK 
and IgG) were directly cloned in pCR2.1 vector (Invitrogen) and expanded 
transforming E. coli cells Mach1TM-T1R (Invitrogen). Screening digestions with 
EcoRI were performed to find positive clones. Human constant light chain regions 
fragments were then digested with AgeI-SalI and ligated into pTY2-CMV-GFP-
IRES-NEO; Human constant heavy chain regions were cloned into pTY2-CMV-
IRES-PURO-WPRE using NheI-HpaI digestions. Subsequently they were 
expanded by transformation of E. coli cells TOP10. When vectors pTY2-CMV-
human_constant_IgK-IRES-NEO and pTY2-CMV-human_constant_IgG-IRES-
PURO-WPRE were ready, the protocol was repeated with murine variable 
regions: light chain regions were digested with AgeI whereas for heavy chain 
regions NheI was used. All endonucleases reactions were performed following 
manufacturer’s instructions. Following endonucleases reactions, all products were 
extracted from agarose gel using Qiagen Gel Extraction Kit. Fragments of 
acceptor vectors were dephosphorylated using Shrimp Alkaline Phosphatase (SAP 
– Promega) and ligated using T4 DNA Ligase (Promega). All protocols where 
performed following manufacturer’s instructions. For ligation reactions an 
insert:vector ratio of 9:1 was used. 
3.12 Sequencing 
PCR and cloning products were sequenced by BMR Genomics. 
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4. RESULTS 
4.1 Antibody analyses by neutralization assays 
4.1.1 Hybridomas screening for neutralization activity 
Hybridomas were obtained from spleen cells of mice immunized with fusion 
complexes of CHO-CD4-CCR5 and CHO-gp120/gp41. A total of 64 selected 
hybridomas supernatants were tested for neutralization activity against several 
HIV-1 isolates belonging to panel B (figure 4.1). The used isolates have 
different sensitivity to neutralization: AC10.0-29 (AC10), moderately sensitive, 
91US005.11 (91US), 6535-3 (6535), QHO692-42 (QHO), sensitive. 
Neutralization assays were performed on the TZM-bl cell line using 200 
TCID50 of each pseudovirus. The antibody Tri-Mab, constituted by three 
different anti-Env monoclonal antibodies derived from LTNP patients (2G12, 
4E10, 2F5), was used as positive control at 1 µg/ml. Neutralization activity was 
expressed as a lowering of light emitted by luciferase, expressed by TZM-bl and 
transactivated by the pseudovirus once infection has taken place. Mean activity 
of all polyclonal populations showed values settling around 30% for isolates 
6535 and QHO, whereas values obtained against 91US and AC10 have a mean 
of about 20% and 0,5% respectively. Among all supernatants analyzed, the one 
produced by polyclonal population SM24 showed values ranging from 50% on 
QHO to 80% on 6535. These results indicated SM24 as a possible candidate for 
subcloning. 
 
4.1.2 Comparison between SM24 and positive control 
Further analyses on SM24 were done comparing supernatant with Tri-Mab 
positive control in a neutralization assay against isolates QHO, 6535 and AC10. 
This assay was performed on TZM-bl cell line using the same amount of SM24 
and Tri-Mab with scale dilution going from 2 µg/ml to 0,12 µg/ml of antibody 
against 200 TCID50 of each pseudovirus. For all tested isolates both SM24 and  
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Figure 4.1 Screening of 64 supernatants, obtained from mouse hybridomas, for 
neutralizing activity against four HIV-1 isolates. Neutralizing activity varies among 
different samples but it is possible to see how supernatant SM24 shows high values 
for all viral isolates. 
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Figure 4.2 The panel shows three different neutralization assays comparing neutralizing 
activities of sample SM24 (red) and Tri-Mab control (blue), against three different HIV-1 
pseudoviruses. A) Against QHO692-42, SM24 and control show very similar trendlines. 
B) Neutralizing activity of SM24 against 6535-3 shows a linear trendline, proportional to 
Tri-Mab, but always about 20% higher. C) Values against AC10.0 show result in a much 
sharper trendline for SM24. 
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Tri-Mab showed a decreasing trend of neutralization activity, proportional to the 
decrease of antibody concentrations. SM24 supernatant showed a neutralization 
activity closely comparable with positive control when directed against QHO 
isolate, going from about 70% at 1,3 µg/ml to 25% at about 0,3 µg/ml (figure 
4.2 A). In particular, analyses against pseudovirus 6535 showed how the 
neutralization trendline of both SM24 and Tri-Mab lowered linearly from 1,8 
'g/ml to about 0,2 'g/ml, giving values going from 80% to 25% for SM24 and 
from 55% to 5% for Tri-Mab. Therefore, for every tested value, SM24 showed a 
higher neutralization curve than the reference Tri-Mab (figure 4.2 B). Using the 
same range of antibody concentrations against AC10 isolate, the given 
decreasing trend is milder for Tri-Mab varying from 25% to 5%, and sharper for 
SM24, lowering from 60% to 1% (figure 4.2 C). Thus, even in this case, SM24 
neutralizing activity resulted to be higher than Tri-Mab activity in both cases.  
4.1.3 Specificity of SM24 IgGs 
Since the amount of neutralization activity of the supernatants could depend 
from antibodies directed against the viral receptors used to produce fusion 
complexes, a test was performed to ensure that IgGs in SM24 supernatant were 
mostly directed to HIV-1 epitopes. Antibody supernatant was pre-adsorbed on 
CHO cells expressing CD4 and CCR5 receptors, and then used in a 
neutralization test against isolate 6535 used at 200 TCID50. Pre-adsorbed 
supernatant was analyzed and compared to non pre-adsorbed sample using 
equivalent scale dilutions going from 1:5 to 1:135 and data were reported as 
percentage of luminescence lowering (figure 4.3). With dilutions up to 1:10, 
neutralization trendline of pre-adsorbed sample shows no differences with non-
pre-adsorbed SM24 reaching 80% for both. Differences in neutralization 
activity could be observed with increasing dilutions, going from 55% to 50% 
(normal and pre-adsorbed respectively) when samples were diluted 1:50, and 
from 40% to 25% for 1:100 dilution. However, despite the drop of the curve, 
neutralization values of pre-adsorbed samples remain high even at low 
concentrations. 
Moreover, to test the specificity of SM24 supernatant we performed a 
neutralization   assay    against    a   pseudovirus   with   the  envelope   VSV-G 
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Figure 4.3 Trend of neutralizing activity of SM24 supernatant dilutions against viral 
isolate 6535-3 before pre-adsorption on cells expressing cell receptors for CD4 (circle) 
and after adsorption (square). The blue line (triangle) represents the activity against a 
pseudovirus expressing VSV-G. 
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 (Vescicular Stomatitis Virus Glycoprotein), which has no similarities with 
HIV-1 glycoprotein gp120/gp41. Supernatant diluted up to 1:10 neutralizes 
VSV-G at about 25% but the  trendline  shows  a  very  quick  decrease  as the 
sample is diluted. The difference between the neutralization curves of SM24 
directed against isolate  6535 and VSV,  indicated that antibodies produced  by 
SM24 population were specifically directed against HIV-1 and neutralize isolate 
6535 at about 60% when undiluted. 
4.1.4 Selection of oligoclonal populations 
SM24 hybridoma cell population was subcloned into subgroups of 20 cells/well. 
A total of 18 supernatants of oligoclonal populations were then screened to 
identify samples with the highest neutralization activity. A neutralization assay 
was performed for 18 supernatants in comparison to SM24 and to Tri-Mab (5 
µg/ml). A wider set of HIV-1 isolates was used: it included additional env- 
expressing-pseudoviruses such as SF162, TROcl-11 (TRO) and pREJ04541 
(pREJ) besides AC10, 6535 and QHO. Except some samples as aC12, eC6 and 
gC1, all oligoclonal supernatants resulted to have a good level of neutralization 
(figure 4.4 A). Generally, the neutralization activity against SF162 isolate was 
higher than SM24 but still lower than the Tri-Mab, whereas other pseudoviruses 
were neutralized better by the supernatants than by the Tri-Mab. For example, 
neutralization values against isolate 6535 where generally very high, with a 
range going from 50% to 90%; QHO isolate was neutralized from 30% to 70%; 
neutralization values against AC10 vary from 30% to 90%; values against TRO 
and pREJ present a wider range going respectively from 20% to 90% and from 
5% to 80%. 
For each sample we calculated mean neutralization values against all used 
isolates and the range of the spectrum covered by the supernatants, to choose 
which oligoclonal populations were to be subcloned to single cell (figure 4.4 B). 
As showed by the neutralization assay, samples gB11 and cG11 gave values 
higher than other samples (above 75%) and low differences among isolates (10-
12%). Together with 9 more supernatants, they were analyzed by whole-cells-
ELISA  assay,  performed in order  to measure  supernatants  reactivity  against  
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Figure 2.4 A) Neutralization analyses performed on 18 oligoclonal supernatants against 6 
different viral isolates and compared with SM24 and Tri-Mab. B) Mean neutralization activity of 
oligoclonal supernatants. 
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Figure 4.5 Comparison between mean neutralization activity of oligoclonal 
supernatants and their reactivity against target cells for neutralization assay. Samples 
gB11 and cG11 show the best ratio neutralization/reactivity therefore are chosen to 
proceed with the study. 
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TZM-bl cells, and to exclude those containing cell specific IgGs (figure 4.5). 
Comparing reactivity against cells obtained by ELISA assay and mean 
neutralizations obtained before, it was possible to observe 5 clones neutralizing 
at 40-50% with TZM-bl reactivity with values between 1,8 and 2,2; 4 clones, 
neutralize at about 60-70% and showed reactivity between 2,2 and 2,5. Clone 
bA9 gave a high neutralization percentage (about 80%) but a very high 
reactivity against cells (about 3,25). Finally, clones gB11 and cG11 showed a 
mean neutralization value of about 80% and 70% respectively, and a low 
reactivity against cells (1,7 and 2,1). Therefore, populations gB11 and cG11 
resulted to be the best available, with the highest neutralization activity, and the 
lowest reactivity against cells. 
4.1.5 Selection of monoclonal antibodies 
gB11 and cG11 oligo-populations were subcloned to single cell populations; 
supernatants of about one hundred clones from each progenitor were then tested 
for neutralization activity against isolate 6535 (sensitive) as previously 
described. On 72 clones derived from cG11 (figure 4.6 A), 63 showed 
neutralization activity. 30% of such clones present an activity within 10%; 50% 
of them neutralized within 20%; 25% reached neutralization between 20% and 
30%. The 5 remaining clones surpassed 30% of neutralization activity; among 
them, clone 8F9 reached 39%. 50 gB11 clones were found and 31 showed 
neutralization activity (figure 4.6 B). Among them, 21 clones reached 10% of 
max neutralization, 11 clones gave a neutralization range between 10% and 
20%, 2 clones surpassed 20% and one clone (10F12) showed a neutralization 
percentage of 35%. 
From here on our attention was focused on gB11 clones. Neutralization activity 
of supernatants was compared with reactivity against target cells, as done for 
oligoclonal supernatants. As shown in figure 4.7, clone 10F12 presented both 
the higher neutralization and the lower reactivity against TZM-bl cells. Clone 
10F12 was thus chosen to proceed with our studies. Firstly, it was tested for 
neutralizing activity against more viral isolates in comparison with Tri-Mab, as 
done for oligoclonal supernatants. Such assay was performed using 5 µg/ml 
antibody. Excluding activity against TRO-11 values against all other viral  
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Figure 4.6 Initial screening of supernatants of monoclonal population obtained 
from cG11 (A) and gB11 (B). Neutralization assays were performed against 
viral isolate 6535-3. Higher neutralization values are found for clones 8F9 (A) 
and 10F12 (B). 
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Figure 4.7 Comparison between neutralization activity of monoclonal supernatants 
from gB11(against isolate 6535-3) and their reactivity against target cells for 
neutralization assay. Sample 10F12 the best ratio neutralization/reactivity therefore is 
chosen to proceed with the study. 
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Figure 4.8 Analyses of neutralization activity of clone 10F12 against several HIV-1 
isolates and against VSV-G, compared with neutralizing activity of control Tri-Mab. 
For all isolates, except TROcl11, values of 10F12 and Tri-Mab are comparable. 
Activity against VSV-G is closed to 0, excluding unspecific neutralization. 
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Figure 4.9 Comparison of neutralization activity of supernatant 10F12 before and after 
clone expansion. 
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isolates were closely comparable. Neutralization values against QHO and AC10 
were found around 20%-25%, whereas values against pREJ04541 were about 
40%. Moreover, neutralization activity against VSV-G pseudovirus was taken 
into account, in order to exclude unspecific activity (figure 4.8). In order to 
produce high titers of antibody, 10F12 cells were cultured into bioreactors, used 
to concentrate IgGs secreted in culture medium. Neutralization assays were 
repeated at each subsequent culture steps in bioreactors; tests showed a decrease 
of neutralization activity as cultures proceeded. Figure 4.9 shows the 
comparison of neutralization activity for 10F12 antibody against pseudovirus 
6535-3 before and after expansion. It is possible to see that, whereas first 
analyses showed a neutralization activity of 35% using 5 µg/ml, after expansion 
a concentration of 30 µg/ml is needed in order to neutralize the pseudovirus at 
about 11%. 
4.2 Construction of vectors expressing humanized IgGs 
In order to stabilize antibody expression our aim was to produce a robust cell 
line, stably expressing the antibody produced by clone 10F12. Furthermore, we 
decided to humanize our murine antibody. 
4.2.1 Amplification of human constant regions starting from PBMCs 
Starting from human PBMCs, total RNA was extracted and retrotranscripted to 
cDNA, which was then used as template for PCR amplification of IgG human 
constant regions of both light and heavy chains. PCR products were analyzed by 
agarose gel electrophoresis (figure 4.10). Human constant light chain (Human 
CK) product is noise-free and shows, as expected, a band of about 300 bp, 
whereas human constant heavy chain (Human CH) analysis showed a smear and 
an unspecific band of about 1200 bp. Nevertheless the specific band of about 
980 bp gives a much stronger signal. 
4.2.2 Amplification of murine variable regions from clone 10F12 
10F12 supernatant was used to isotype the IgGs produced by 10F12 cells, and 
resulted to express murine light chain K and heavy chain G2b. Clone 10F12 was 
then used to extract total RNA, then retrotranscripted by random primers and 
used as template for amplification of murine light and heavy chains variable 
regions. Based on isotyping results, PCRs were performed using a subtype  
                                                                                                                     Results 
 
! &$!
  
Figure 4.10 PCR amplification of human IgG constant regions: on the 
left we find light constant region (Human CK) around 300 bp; on the 
right is the heavy constant region (Human CH) of about 980 bp. 
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Figure 4.11 PCR amplification of murine IgG variable regions, performed using pools 
of degenerated primers. On the left heavy chain variable regions are visible, whereas 
on the right there are light chain variable regions. Red squares indicate the chosen 
fragment to proceed with our studies. 
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specific reverse primer, IgK for light chain and IgG2b for heavy chain. As 
forward primer, we used pools of degenerated primers, divided in seven groups  
for light chain (A-F) and six groups for heavy chain (A-G) each of them 
including from one to four primers. PCR products were analyzed for correct size 
by agarose gel electrophoresis. Expected size for both variable regions was 
about 420 bp. On the left of figure 4.11, results for murine heavy chain variable 
region are shown; each lane indicates the group of forward primers used for 
amplification. Products obtained with primers group A and F give a weak 
signal; results obtained with groups B, C and E show strong background and 
weak specific band, whereas group D resulted in a strong and clean  signal of 
correct size.  
For murine light chain variable region (figure 4.11 on the right), primers groups 
A and F gave no amplification and groups B and C showed weak bands and 
unspecific signals; finally, groups D, E and G gave strong bands of correct 
sizes, but product G resulted in a cleaner signal. Products obtained with primers 
from group D (variable region of heavy chain) and from group G (variable 
region of light chain) were selected. 
 
4.2.3 Generation of vectors expressing human constant regions 
PCR products of light and heavy chains constant regions, obtained from human 
PBMCs, were cloned into plasmid pCR2.1 and used to transform E. coli cells. 
Colonies were then screened by EcoRI digestion and analyzed on agarose gel to 
confirm fragments insertion. Expected bands were about 350 bp for light chains 
and 950 bp for heavy chains. As shown in figure 4.12 A, most of light chain 
constant regions were successfully cloned into plasmid pCR2.1; exceptions are 
samples 4 and 7, showing no insertion, and 9,10 and 11, whose fragments 
resulted higher than expected. Concerning constant heavy chain, figure 4.12 B 
shows how about 50% of colonies contain the inserts of interest; exceptions are 
samples 3, 5 and 9, showing non insert, and samples 6 and 11 showing bands 
with sizes differing from expectations. One colony for constant-IgK (sample 3) 
and one for constant-IgH (sample 2) were then chosen to be amplified by 
midiprep and ligated into pTY2-CMV-GFP-IRES-NEO and pTY2-CMV-IRES-
PURO-WPRE respectively, which express Neomycin (former) and Puromycin  
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Figure 4.12 Sequential steps for production of vector containing human IgG contant 
regions. A) EcoRI digestions of minipreps after TA cloning protocol for constant light 
chain regions. B) EcoRI digestions of minipreps after TA cloning protocol for constant 
heavy chain regions. C) Screening for successful insertion of constant light chain 
regions inside pTY2-CMV-GFP-IRES-NEO by AgeI-SalI digestion. D) Screening for 
successful insertion of constant heavy chain regions inside pTY2-CMV-IRES-PURO-
WPRE by NheI-HpaI digestion. 
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(latter) resistance. Once again, ligation products were used to transform E. coli 
cells and colonies were then screened by enzymatic digestion, AgeI-SalI for K- 
chain and NheI-HpaI for H-chain. Digestion products were then analyzed on 
agarose gel. As shown on figure 4.12 C, light chain colonies were almost all 
positive, containing Human CK inserts. Concerning constant regions of heavy 
chains (figure 4.12 D) one colony containing the insert (sample 4) was found. 
By amplification of positive colonies we obtained vectors expressing human 
constant regions of light and heavy chains, which will be used to build vectors 
expressing humanized chains. 
4.2.4 Generation of vectors expressing humanized heavy and light chains 
PCR products obtained from hybridomas cell clone 10F12 were inserted into 
plasmid pCR2.1 and used for E. coli cells transformation. Colonies were 
screened by EcoRI digestion and molecular weight controlled on agarose gel. 
Figure 4.13 A shows results for variable light chain (IgKv) on the left; almost 
all colonies show presence of the insert with bands of about 420 bp. On the right 
side are the colonies for variable heavy chain, which confirm occurred insertion 
with bands of about 420 bp. One sample for each chain was then chosen to be 
ligated into vectors bearing human constant light and heavy chains. Ligation 
products were used to transform E. coli cells, and colonies were then analyzed 
on agarose gel. Cloning of human constant regions employed AgeI-SalI and 
NheI-HpaI digestions for light and heavy chains respectively; insertion of 
murine variable chain regions makes use of AgeI and NheI digestions, attaching 
variable regions upward to constant regions. Because of this, screening by 
digestion was not possible, since AgeI or NheI reactions would not tell us the 
correct orientation of inserts; therefore positive clone were identified by PCR, 
using reverse primers of constant regions and forward primers of variable 
regions. Thus we can verify not only the insertion of variable regions, but also 
their correct orientation. In figure 4.13 B we can see PCR products for 
humanized IgK: samples 2, 3, 6, 7, 11 and 12 show clean bands of correct sizes 
(about 750 bp). Concerning PCR products for humanized IgG (figure 4.13 C) 
colonies 3, 6, 7, 11 and 12 show cleaner signals, with bands of the correct size 
(about 1400 bp) and an upper unspecific band. IgK sample 12 and IgG sample 7 
. 
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Figure 4.13 Sequential step for production of vectors expressing humanized IgG and 
IgK. A) EcoRI digestions of minipreps after TA cloning protocol for murine variable 
light chains (left) and heavy chains (right). B) PCR Screening for successful insertion 
of variable light chain regions inside pTY2-CMV-GFP-IRES-NEO; insertion is correct 
when PCR amplifies a full length sequence for humanized IgK (750 bp). C) PCR 
screening for successful insertion of variable chain regions inside pTY2-CMV-IRES-
PURO-WPRE ; insertion is correct when PCR amplifies a full length sequence for 
humanized IgG (about 1400 bp). 
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were selected to proceed with our studies. Figure 4.14 summarizes the protocol 
used to produce vectors expressing humanized light and heavy chains. 
4.2.5 Vectors control 
Original vectors, as well as newly generated ones have a high probability to 
form recombinants because of the presence of LTR regions. Thus, they were 
digested with different restriction enzymes, comparing new vectors with 
original vectors. pTY2-NEO vectors were digested with AgeI, BamHI, and PstI: 
AgeI digestion should linearize original vector and separate murine variable 
light chain (420 bp) from new generated vector; BamHI should give same 
results on both vectors since humanized IgK replaced GFP and non of them 
shows a BamHI site; PstI digestion should also result as very similar bands for 
both vectors, with a 20 bp difference in upper bands. On pTY2-PURO vectors 
we used NheI, BamHI and a mix of AgeI and SalI. NheI should linearize 
original vector and separate murine variable region (about 420 bp) on the new 
one; BamHI digestion is expected to result in three bands on original vector and 
for bands on the new one. In this case the two upper bands will be identical, 
whereas the lower band of original vector (927 bp) will be replaced by two 
heavier bands due to the presence of a restriction site on IgG. Digestion 
performed using AgeI-SalI will result as two bands for pTY2-CMV-IRES-
PURO-WPRE vector and three bands for pTY2-CMV-humanized_IgG-IRES-
PURO-WPRE vector, due to the presence of an additional AgeI site on the 
transgene. As showed on figure 4.15 all our expectations were validated. 
4.3 Production and analysis of humanized IgGs 
4.3.1 Lentiviral vectors construction 
The newly constructed vectors expressing humanized IgK and IgG were used to 
produces two third generation lentiviral vectors, one for each chain, expressing 
VSV-G envelope proteins and bearing humanized IgK or IgG respectively. This 
was done performing two separate quadruple co-transfections in 293T cell line 
of either pTY2-CMV-Humanized_IgK-IRES-NEO or pTY2-CMV- 
humanized_IgG-IRES-PURO-WPRE with ENV plasmid (VSV-G), pMDLg/ 
pRRE and pRSV-REV. After 48 hours from transfection cells supernatants, 
containing lentiviral vectors, were harvested and filtrated (figure 4.16). 
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Figure 4.14 Schematic representation of the steps involved to produce vectors 
bearing constant regions of human IgG and final vectors expressing humanized 
IgG. 
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Figure 4.15 Control digestion for final vectors pTY2-CMV-Humanized_IgK-IRES-NEO  
(left) and pTY2-CMV-humanized_IgG-IRES-PURO-WPRE (right). “O” indicates the 
original vectors, whereas “N” stands for new vectors. All digestions confirmed the 
correct insertion of humanized chains. 
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Figure 4.16 Schematic representation of production of viral vectors expressing 
humanized IgG light and heavy chains, and their use to produce a cell line stably 
expressing humanized IgG. 
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4.3.2 Productions of the CHO cell line expressing humanized IgGs 
Freshly prepared lentiviral vectors were used to co-infect the CHO cell line. 
Lentiviral vectors have the ability to integrate their genome inside host cell 
genome. CHO cells infected by both vectors will develop resistance to 
Puromycin and Neomycin. After 48 hours from co-infection cells were placed 
under selection conditions with Puromycin (5 'g/ml) and Neomycin (100 
'g/ml). As a negative control, this was performed on non-infected cells. After 
24 hours non-infected cells were dead whereas co-infected cells showed a 
healthy population (figure 4.16 – 4.17). 
4.3.3 Analysis of transgenes integration 
To verify the presence of humanized IgGs in the genome of CHO cells, 
genomic DNA of resistant and non-resistant cells was extracted and used to 
perform PCR of both chains, using murine variable chains primers as forward, 
and human constant chains primers as reverse. DNA extracted from non-
infected CHO cells was used as negative control whereas plasmids expressing 
humanized chains were used as positive controls. Figure 4.16 shows on the left 
side, amplifications results for humanized murine heavy chain (MuHu-IgG): 
genomic DNA of co-infected cells was amplified to the correct size (about 1400 
bp), as well as the positive control, represented by pTY2-CMV-
humanized_IgG-IRES-PURO-WPRE; genomic DNA of normal CHO cells gave 
no amplification as expected. On the right side PCR products for humanized 
murine light chain (MuHu-IgK) can be analyzed: as for MuHu-IgG, genomic 
DNA of co-infected cells gave a single clean signal of the correct size (about 
750 bp), obtained as well with positive control, which showed unspecific bands 
due to its high concentration; genomic DNA of CHO cells, and blank sample, 
gave no signal. 
4.3.4 Analysis of humanized IgG production 
After one week of selective conditions, co-infected CHO cells were cloned to 
single cell populations. Growing clones were expanded from 96-well plate to 6- 
well plate. In order to verify the expression of humanized IgG, and select the 
clone with higher antibody production, an ELISA assay directed against human 
Fc was performed on the supernatants of CHO clones. 
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Figure 4.17 Schematic representation of co-infection of CHO cells using viral vectors 
expressing humanized light and heavy chains; with double selection (neomycin and 
puromycin) only cells with integrated copies of both transgenes survive. Such cells 
produce humanize antibodies. 
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Figure 4.18 PCR analyses for integration of humanized heavy (left), and light (right) 
chain inside CHO genome. Genomic DNA of co-infected CHO cells was used. As 
positive controls pTY2-CMV-humanized_IgG-IRES-PURO-WPRE and pTY2-CMV-
Humanized_IgK-IRES-NEO were used. Normal CHO cells genomic DNA was used as 
negative control. 
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Figure 4.19 ELISA screening for humanized IgG production on clones derived from co-
infected CHO cells. Clones EF1, CE3, EB12, DB8, and EF9 show to produce 
humanized IgG. Normal CHO supernatant (red) is the negative control, whereas 
complete DMEM (blue) is used as blank. 
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The supernatant of non-infected CHO cells was used as negative control, and 
complete DMEM was used as blank. Most of the tested supernatants (twenty-six 
on thirty-one), gave values comparable to negative control and blank samples. 
The remaining five clones gave higher values, included inside standard curve 
scale. These are: EB12 (13,6 ng/ml), DB8 (14,7 ng/ml), CE3 (32,1 ng/ml), EF1 
(41,1 ng/ml) and EF9 (43,1 ng/ml). 
4.3.5 Neutralization test on humanized antibody 10F12 
A preliminary neutralization assay was performed on concentrated humanized 
10F12 (h10F12) antibody supernatant of CHO clone EF9. As controls, murine 
10F12 (m10F12) antibody was used, as well as human monoclonal antibodies 
2F5 and 4E10. The sample h10F12 was used at a concentration lower than 1 
'g/ml, whereas controls were used at 30 'g/ml (m10F12) and at 10 'g/ml (2F5 
and 4E10). Viral isolates QHO, AC10 and VSV-G (negative control) were used 
at 200 TCID. As target cell, TZM-bl, TZM-bl-Fc%RI and TZM-bl-Fc%RIIb were 
used in order to verify different pathways of neutralization specific for human 
antibodies. In figure 4.20a, neutralization values against isolate AC10 are 
shown: on TZM-bl cells, neutralization activity of the h10F12 is about 70%, 
compared to 90% of m10F12, 75% of 2F5 and 65% of 4E10. Values with TZM-
bl-Fc%RI and TZM-bl-Fc%RIIb are similar for h10F12, going from 70% to 80%, 
whereas the activity of the murine antibody is about 50%; 2F5 and 4E10 kept 
high neutralization values going from 80% to 95%. Neutralization activity 
against isolate QHO of the humanized antibody remained around 80% for all 
types of cells (figure 4.20b), resulting slightly higher than 2F5 and 4E10 on 
TZM-bl and on TZM-bl-Fc%RIIb cells, whereas on TZM-bl-Fc%RI human 
monoclonal antibodies values are slightly higher. Neutralization assay against 
VSV-G (figure 4.20c) showed an unspecific activity of humanized antibody 
supernatant on TZM-bl and TZM-bl-Fc%RI cells (50% and 20% respectively), 
whereas on TZM-bl-Fc%RIIb cells, values were negative. Murine 10F12 showed 
unspecific values against TZM-bl (15%) and negative values on the derivative 
cells. Values of 2F5 and 4E10 against VSV-G were close to 0% or negative, on 
all types of cells. 
  
                                                                                                                     Results 
 
! ')!
!
Figura 4.20 % of neutralization performed using the humanized antibody supernatant 
(h10F12), murine 10F12 (m10F12) and human monoclonal antibodies 2F5 and 4E10 
against viral isolate AC10 (A), QHO (B) and the negative control VSV-G. Obtained 
values indicate the functionality of humanized antibody. 
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5. DISCUSSION 
Many broad-spectrum neutralizing antibodies currently available were identified 
in HIV-seropositive patients (e.g. 2F5, 4F10, 2G12, b12, 17b, HJ16, HGN194, 
HK20, PG16) (Qakkelaar et al., 2007; Corti et al., 2010; Pejchal et al., 2010). 
Therefore, the immunogenic structures that activate such antibodies in vivo are 
unknown. Moreover, some of them (2F5, 4E10) show certain reactivity against 
self antigens (Haynes et al., 2005). Thus, the exploitation of known antigenic 
structures is highly necessary for the development of new immunogenic agents 
and the isolation of new broad-spectrum antibodies. 
The immunization with fusion complexes to induce a broad-spectrum neutralizing 
response is based on the possibility to obtain fusion intermediates between HIV-1 
proteins gp120/gp41 and cell receptors, using sub-optimal temperatures. In these 
conditions conserved structures and epitopes, usually hidden inside the protein 
structure of the viral envelope, are exposed and stabilized. Using fusion 
intermediates as immunogenic agents induced a specific immune response in 
mice, which was able to neutralize the infection of competent cells by different 
viral isolates in vitro (Zipeto et al., 2006). 
Despite such results, indicating the possibility to use fusion complexes to elicit a 
neutralizing antibody response against HIV-1, the employment of immunogenic 
agents constituted by fixed cells cannot be applied in clinical studies. Moreover, 
the purification of fusion complexes (described in Zipeto et al., 2006 and Xiao et 
al., 2003) cannot be exploited for large-scale production of a vaccine. The 
isolation and study of monoclonal neutralizing antibodies obtained with fusion 
complexes, could allow the exploitation of such antibodies in protection studies 
on animal models (in vivo).  
For isolation of neutralizing monoclonal antibodies, mice immunized with fusion 
complexes fixed with PFA were employed for hybridoma populations production. 
To select hybridomas secreting antibodies of interest, a functional screening was 
used, based on usage of neutralizing activity against single infection cycle HIV-1 
pseudoviruses (Li et al., 2005). Such protocol is highly sensitive, standardized and 
reproducible (Louder et al., 2005). About 8% of hybridomas populations, tested 
with four different pseudoviruses, were able to show a neutralizing activity above 
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40%. Few of them showed high neutralization values against less sensitive clades; 
among them, sample SM24 showed neutralization values between 50% and 80%, 
generally higher than the positive control (Tri-Mab). Such results indicate 
production of neutralizing antibodies from immunized mice as well as a good 
immunogenic function of fusion complexes. 
Since the use of fusion complexes can bring to development of antibodies directed 
against either cell receptors (CD4, CCR5, CXCR4) or other cellular proteins, 
SM24 supernatant was pre-adsorbed on CHO cells expressing CD4-CXCR4-
CCR5, which were used to produce fusion complexes. In addition, its specificity 
was tested against a pseudovirus with VSV-G envelope.  
Sample SM24 proved to contain antibodies specific for HIV-1 envelope epitopes 
as the whole neutralizing activity was not affected by removal of reactivity against 
CD4, CCR5 and CXCR4 molecules. Such results prove the specificity of SM24 
antibody supernatant against HIV-1. Moreover they indicate possible exposure, in 
fusion complexes, of important, highly immunogenic, HIV-1 conserved epitopes.  
Supernatants of polyclonal populations contain antibodies directed against 
different epitopes. On one hand, this could result in a synergic activity of 
antibodies and a consequent higher neutralization rate; on the other hand, the 
population with higher growth rate could become predominant, resulting in an 
excess of one particular antibody, which is not necessarily the one with higher 
neutralization. Indeed, side-expansion of polyclonal population SM24 brought to 
gradual reduction of neutralizing activity (data not shown). For this reason, and in 
order to isolate cellular clones responsible for the observed activity, total 
population of the chosen sample was subdivided into smaller cellular sub-groups 
(oligoclones). Neutralization assays performed on oligoclone supernatants using 
different pseudoviruses, some of which highly resistant to neutralization, showed 
a neutralizing activity of at least 30% with all used pseudoviruses for almost all 
sub-populations confirming the values obtained for SM24.  
In order to exclude samples whose activity was not HIV-1 specific, samples with 
higher neutralization were tested for their reactivity against target cells. Two 
samples showing the higher neutralization/reactivity ratio were chosen for single-
cell sub-cloning. Supernatants of resulting clones were then tested again for 
neutralization activity against an easily neutralized pseudovirus, showing a certain 
degree of neutralization activity. General neutralization of oligoclonal 
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supernatants resulted higher when compared to monoclonal supernatants; the 
reason might be due to a synergic effect of combined antibodies. 
As gB11 supernatant showed a lower reactivity against target cells, and therefore 
it is HIV-1 specific, we chose to proceed our studies by analyzing antibody 
supernatants obtained by single cell cloning of gB11 oligoclone. After the first 
screening against viral isolate 6535-3 samples were analyzed for their reactivity 
against target cells, in order to exclude unspecific neutralization activity. Sample 
10F12, which showed the higher neutralization values, resulted to be also the 
sample with lower reactivity against target cells. It was thus tested against 
different HIV-1 isolates, in order to verify its broad-spectrum activity. As control 
a VSV-G pseudovirus was also used, to further exclude unspecific reactivity. 
Results show that the reactivity of sample 10F12 was highly similar to that of Tri-
Mab for all tested viral isolates except one (TRO-11). The results obtained in the 
analyses of 10F12 antibody supernatant indicated a possible broad-spectrum 
activity of such antibody, which is also characterized by HIV-1 specificity and 
low toxicity over cells; therefore clone 10F12 was designed as a good candidate 
for further analyses. 10F12 cells were thus placed into bioreactors, to obtain 
medium with high antibody concentration, which was harvested and analyzed 
once a week. 
Unfortunately, after some cultivation cycles, the neutralization ability of 
supernatant 10F12 dramatically lowered. Reasons for such loss of neutralizing 
activity are not confirmed, but antibody producing clones derived from 
hybridomas need to be kept in constant sub-cloning conditions, in order to 
maintain a high antibody activity. Indeed, it is well known that additional 
problems can arise when the growth of “stable” high-yield hybridomas is scaled 
up for mass production and either synthesis or activity drop off for no apparent 
reason (Albright & Janick, 1987). 
As a consequence, stable production of a functional antibody is absolutely 
necessary. Indeed, in order to fully understand the features of an antibody, several 
analyses for characterization are needed. Therefore, our aim was the cloning of 
sequences of the 10F12 cells that encode murine IgG protein, in order to include 
them in a stable expression system. 
A further objective was the humanization of IgG antibody produced by the clone 
10F12. Tri-Mab, the positive control used in our neutralization, assay is a mixture 
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of three human monoclonal antibodies; therefore the usage of humanized 
antibodies for our test would permit a more reliable comparison of neutralizing 
activity. Moreover, it is known how human antibodies, compared to murine, show 
a more flexible structure thanks to the hinge region, which separates Fc from Fab 
(Dorrington and Klein, 1981). As a result, human antibodies can adapt their shape 
more easily when compared to murine antibodies. Thus, there is the possibility 
that humanization of a murine antibody could result in a more functional protein. 
Finally, a humanized antibody could be administered to patients for therapeutic 
trials. 
In order to humanize our antibodies we designed groups of primers to amplify the 
constant regions of light and heavy chains of human IgG, and variable regions of 
light and heavy chains of murine IgG. This way it would have been possible to 
match variable and constant regions inside expression vectors, thus producing 
full-length sequences for humanized light and heavy chains. 
For primer design, our study was inspired by the work of McLean (McLean et al., 
2000), who produced immunoglobulin expression vectors to be used in the 
production of recombinant Ig molecules in transfected mammalian cells. In 
particular, reverse primers for human constant light and heavy chains were 
designed on the primers described as (-antisense and %-antisense, changing the 
cleavage sites inside them. Forward primers for the same regions were newly 
designed in order to match the cleavage site placed on murine variable regions 
and to obtain a functional open reading frame. Primers for murine variable regions 
were based on commercial primers produced by Novagen. Punctual amplification 
of DNA fragment of the correct size demonstrated the proper functioning of the 
designed primers. 
The main innovation in this work is the development of a method to produce a 
cell line that could stably express a recombinant antibody. The usage of lentiviral 
vectors to transduced eukaryotic cells is an optimal solution to achieve a stable 
expression, due to their ability to integrate the transgene inside the genome of 
target cells. When the transgene is integrated inside an active region, with no 
interruption of genes vital for host cells, it will provide a stable cell line 
expressing the recombinant protein of interest, which in our case is a humanized 
antibody against HIV-1. To isolate cells with successful transgene integration 
single cell cloning is essential, in order to select producing clones. 
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Nearly 70% of all recombinant proteins produced today are made in Chinese 
Hamster Ovary (CHO) cells (Jayapal et al., 2007). Their adaptive ability and ease 
of maintenance have been exploited in many fields of basic bioresearch. The 
choice of host cells for protein expression has a profound impact on product 
characteristics and maximum attainable yields. CHO cells possess many of the 
characteristics needed for a good host cell, as the ability to be adapted and grow in 
suspension instead of adherence, allowing volumetric scalability and use of 
stirred-tank bioreactors. Moreover they are amenable to genetic modifications 
allowing easy introduction of foreign DNA and expression of large amount of the 
desired protein. 
Results demonstrated successful insertion of both the transgenes (light and heavy 
chain), each transduced by a single lentiviral vector. Evidence can be seen in the 
growth of co-infected CHO cells after establishment of selective conditions. As 
mentioned before, downstream both transgenes there is an IRES region, after 
which genes for antibiotic resistance were placed (neomycin after light chain and 
puromycin after heavy chain). Therefore, in cells growing under selective 
conditions the selected transgenes were necessary integrated inside an active 
region. As a matter of fact, PCR amplification of humanized light and heavy 
chains, obtained from the genomic DNA of co-infected CHO cells, clearly 
confirmed the integration of our transgenes inside the cell genome. Altogether, 
obtained results confirmed the ability of viral vectors to integrate inside the host 
cell. 
After single-cell cloning, supernatants were analyzed for production of humanized 
antibodies, and 5 producing clones were identified. Thus ELISA assays confirmed 
transgenes integration and expression. 
In order to analyze the activity of the “humanized” antibody, a functional assay 
based on calculation of neutralization activity was performed. Therefore, the clone 
with the highest antibody production (EF9) was expanded, and supernatant was 
then concentrated to increase antibody concentration. Afterwards the concentrated 
supernatant was analyzed by neutralization assay, performed on two more variants 
of TZM-bl (TZM-bl-Fc%RI and TZM-bl-Fc%RIIb), which are specific to analyze 
human antibodies that neutralize by Antibody-Dependant Cellular Cytotoxicity 
(ADCC). The results of the neutralization assay indicated high functionality of the 
humanized antibody. Indeed neutralization values of humanized 10F12 (h10F12) 
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obtained against viral isolate QHO and AC10 were predominant over the values 
obtained with original 10F12 (m10F12). Indeed, even though murine 10F12 
showed higher values against AC10 on TZM-bl cells, it is used at 30 'g/ml, 
whereas the humanized antibody concentration was lower than 1'g/ml. Moreover, 
m10F12 values against QHO are about 50%, whereas values for h10F12 are over 
80%. The murine 10F12 did not show neutralizing activity using TZM-bl-Fc%RI 
and TZM-bl-Fc%RIIb cells, as they are used to specifically test human antibodies. 
The observation that h10F12 worked on FcR-expressing cells, is an additional 
evidence of the production of humanized antibodies. Furthermore, comparing 
h10F12 with positive controls 2F5 and 4E10, results are far more encouraging as 
neutralization values are analogous. Concentrating the humanized antibody 
eventually brought to the concentration of other proteins in cell supernatant, 
which could interfere with the assay. These preliminary results are encouraging, 
but they need to be confirmed after large-scale production and protein G 
purification of the antibody. Nevertheless for TZM-bl-Fc%RI and TZM-bl-
Fc%RIIb, which bind to Fc region, the test is much more specific. Indeed the low 
neutralization values observed against VSV-G on these cells show high specificity 
against HIV-1. Moreover, values obtained with TZM-bl-Fc%RIIb suggest that the 
produced antibody is specific for ADCC mediated neutralization, similarly to 2F5 
reference antibody on TZM-bl-Fc%RI, as recently described (Tudor and Bomsel, 
2011). Therefore, even though clones gave low antibody titers (a maximum of 50 
ng/ml for non-concentrated EF9 supernatant) results obtained with humanized 
10F12 suggests the functionality of the humanized antibody.  
There could be multiple reasons for low antibody production. Though CHO cells 
are not a lymphoblastoid cell line, they are used to successfully produce high 
yields of recombinant antibody. Nevertheless a soluble sialidase that can degrade 
recombinant glycoproteins expressed in Chinese hamster ovary (CHO) cells was 
isolated (Warner et al., 1993) so it would be necessary to check the activity of 
such protein in our co-infected cells. On the other hand, the heavy chain:light 
chain polypeptide ratio inside the host cell is an extremely limiting factor. In 
particular, in stably transduced cells, light chain expression needs to be slightly 
higher than heavy chain as overabundant heavy chain is not folded and is 
trafficked to the proteasome for degradation (Schlatter et al., 2005). Though 
vectors titration was possible by p24 analysis, the result would not have been a 
                                                                                                                  Discussion 
 
! (&!
real infection titration, as count of p24 does not reveal the number of infective 
particles; therefore the amounts of infective particles of viral vectors were not 
measured for co-infection. In this case, there are good chances of disequilibrium 
of insertion of one chain over the other. For this reason, protocol for co-infection 
needs to be devised. Finally, the primers designed for human heavy chain constant 
regions can amplify any of human IgG isotype (IgG1, IgG2, IgG3, IgG4), and 
amplification of constant regions was performed on cDNA derived from human 
PBMCs, without the chance to select the isotype before cloning. On the other 
hand, reverse primers for murine variable chains are specific for the murine 
isotype (IgG1, IgG2a, IgG2b) and hybridomas clone 10F12 produced murine 
isotype IgG2b. Eventually non-IgG2 human constant regions were matched with 
variable regions of murine IgG2b. Though no information confirming possible 
issues deriving from such condition was found, it could, after all, upset the normal 
production of the antibody protein. 
When all this possibilities are taken into account, an antibody production of 50 
ng/ml, against a mean production of 1 µg/ml for hybridomas (20-fold higher) is 
not so embarrassing. The results obtained are a good proof of concept for the 
method discussed in this work. 
As future perspective, confirming the functionality of antibodies produced with 
this method is our first objective. Our intention is to use the viral vectors 
described in this work to humanize a well-characterized murine antibody and use 
the humanized antibody in western blots and ELISA assays thus further verifying 
its functionality. 
In order to minimize variables, after isotyping of murine antibody, human cells 
producing the corresponding human isotype will be used to extract RNA and 
amplify the corresponding constant heavy chains. Furthermore a method to 
measure the viral vectors titer will be studied, and humanized antibodies will be 
purified with protein G. 
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137 Presence and role of HLA-C in HIV-1 infection
Andrea Matucci1, Paola Rossolillo1, Marco Turci1, Pierpaolo Racchiolli1, Antonio 
G. Siccardi2, Alberto Beretta2 and Donato Zipeto1
1Section of Biology and Genetics, University of Verona, Italy and 2San Raffaele Scientific Institute, Milan, 
Italy
Background: A whole genome association study reported a SNP at -35Kb from the HLA-C gene 
strongly associated to HIV-1 viral set point and HLAC expression level (Fellay J. et al., 2007). HLA-C is 
not down-modulated by HIV-1 Nef and can be specifically incorporated in viral membrane enhancing 
infectivity and resistance to neutralizing antibodies (Cosma A. et al., 1999). We investigated the role of 
HLA-C in modulating HIV-1 infectivity using cell fusion and pseudovirus infection models and the inter-
action between HLA-C and Env at membrane level and in purified fusion complexes.
Methods: Human cell lines expressing different HIV-1 gp120/gp41 were specifically silenced for HLA-C 
expression. Cells or pseudoviral particles were used for fusion and single-cycle infection analysis with 
TZM-bl cells. Fusion efficiency and viral infectivity were compared. Fusion complexes from fusing cells 
were purified and the molecular proximity of HLA-C and Env was analyzed by using BRET2.
Results: The absence of HLA-C significantly decreased the fusion efficiency of cells expressing differ-
ent R5 and X4 tropic gp120/gp41s. Similarly, pseudovirus infectivity was significantly reduced if they 
were produced on HLA-C silenced 293T cells. The X4 tropic NDK Env was insensitive to HLA-C at higher 
infectious doses. VSV-G pseudovirus used as control was not sensitive to HLA-C presence. HLA-C could 
be detected associated to gp120 in cells taken before fusion, albeit a stronger association was evident 
during fusion process with target cells.
Conclusions: The co-expression of HLA-C with X4/R5 HIV-1 Env increases the fusogenicity of cell lines 
and the infectivity of pseudotyped viruses. This data point to a specific interaction between HLA-C 
and gp120 on the cell surface membrane. HLA-C and gp120 increase their association during fusion 
complex formation. This interaction can stabilize Env trimers, increasing the kinetic of conformational 
changes or the exposure of the receptor and/or coreceptor binding site favoring membrane fusion. 
Inhibiting the HLA-C/Env interaction might be of great importance in reducing virus infectivity and 
become the rationale for the development of new inhibitors of HIV-1 entry.
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143 Broad Spectrum Neutralizing Antibodies Against 
 HIV-1 Elicited by Immunizing with Fusion Complexes
P. Rossolillo1, A. Matucci1, P. Racchiolli1, L. Mainetti2, S. Dispinseri1, G. Scarlatti2 
and D. Zipeto1 
1University of Verona, Italy, 2DIBIT-HSR, Milan, Italy
Background: The development of neutralizing antibodies against HIV-1 is of pivotal importance for 
the development of an AIDS vaccine. We immunized mice with fusion complexes and elicited antibod-
ies with neutralizing activity against heterologous HIV-1 isolates (Zipeto et al., Microb Infect 2006).
Methods: We prepared murine hybridomas from mice whose sera showed the highest neutralizing 
activity. Their supernatants were tested for reactivity against cells expressing CD4 and CCR5, gp120/41, 
and the gp120/CD4 complex formed by capture ELISA. Hybridoma antibodies with no reactivity 
against HIV-1 receptors were selected. IgGs were purified and tested for their neutralizing activity (1-5 
µg/ml) using both the TZM-bl neutralization assay (Li M. et al, J Virol 2005) and pNL4-3.Luc.R-E- based 
pseudoviruses on U87R5 cells with the standard group B Env panel. Specificity was tested against 
the VSV-G envelope protein. The neutralizing activity of selected antibodies was confirmed using the 
PBMC-based neutralization assay (Polonis VR et al, Virol 2008).
Results: We screened 150 different hybridoma groups; 8% showed a neutralizing activity higher than 
40% and 1 between 50 and 80% against the different pseudoviruses tested, similar or higher than 
the Tri-mAb positive control. Cells from this hybridoma group were cloned; 7% showed a neutralizing 
activity higher than 40% and 2% higher than 50%. Among the latter as many as 44% showed a neu-
tralizing activity higher than 75% against the different pseudoviruses tested.
Conclusions: Hybridomas produced from mice immunized with fusion complexes secrete antibodies 
neutralizing a panel of HIV-1 clade B Envs. We are screening monoclonal antibodies for their broad 
spectrum neutralizing activity against HIV-1. The isolation of such monoclonal antibodies will be of 
great interest for the development of an AIDS vaccine.
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HLA-C presence increases human immunodeficiency type 1 (HIV-1) infectivity by interacting 
with the envelope glycoprotein gp120/41. 
Marco Turci1, Pierpaolo Racchiolli1, Dalila Astone1, Alessandra Ruggiero1, Antonio Siccardi2, Alberto Beretta3, 
Donato Zipeto1 
1Section of Biology and Genetics, DMIBG, University of Verona, Verona, Italy 
2San Raffaele Scientific Institute, Milan, Italy 
3Infectious Diseases Clinic, San Raffaele Scientific Institute, Via Stamira D’Ancona 20, 20127 Milan, Italy. 
INTRODUCTION: HLA-C is among the major genetic determinants for host control of HIV-1 and is incorporated into 
HIV-1 envelope, associates with HIV-1 gp120/41 and increases virus infectivity. Aim of this study is to obtain a 
detailed analysis of the interaction between HLA-C and HIV-1 gp120/41 to understand its biological consequences.  
METHODS: We prepared fluorescent HLA-C and gp120/41, to study their interaction during biosynthesis, intracellular 
transport and membrane localization using BiFC and FLIM. To identify gp120 domains involved in the association with 
HLA-C, different deletion mutants, as well as an HLA-C insensitive gp120, will be tested. RESULTS: Gp120/41 and 
HLA-C, tagged with the two YFP fragments Yc and Yn, were produced in mammalian cells and their expression 
verified. BiFC experiments revealed a direct proximity of gp120/41 and HLA-C, with the putative interaction localizing 
at the RE level. Colocalization analysis between complemented gp120/41 and HLA-C and the Golgi vescicules will be 
performed with using Organellight Golgi-RFP. In addition, the Venus fluorescent tag will be tested. DISCUSSION: The 
finding that HLA-C is involved in increasing HIV-1 infectivity through a direct association with gp120 suggests that 
gp120 trimers conformation on HIV-1 envelope is influenced by HLA-C. This interaction involves the expression of 
neutralization epitopes. This study will allow to define the molecular interaction between HLA-C and gp120, leading to 
the indentification of specific HLA-C binding regions in gp120. This will allow to influence viral infectivity by 
interfering with this specific interaction. 
 
19 
HPV16 affects the expression of ErbB-family receptors during carcinogenesis. 
Paolini Francesca, Silvio Flamini, Elisa Muccioli, and Aldo Venuti. 
Regina Elena Cancer Institute , Rome, Italy 
The ErbB tyrosine kinase receptors are involved in a complex network of signal transduction pathways, playing a key 
role in regulating many cellular functions. Co-expression of these receptors favours omo-hetero-dimerization among 
them, enhancing tyrosine-kinase activity promoting the phosphorylation of several tyrosine residues which leads to a 
complex signalling cascade. The third oncogene of HPV, the E5 protein, interacts with the trasductional pathway of 
different growth factor receptors including  the EGFR. Moreover the HPV-16 E5 can abrogate ErbB4-induced c-Jun 
protein expression resulting in increasing cell proliferation. Beside the E5, all the early proteins of high risk HPV may 
regulate the growth factor signalling pathways and therefore,  the relationship among all these viral genes and the ErbB-
family receptors has been analysed.  In this study the  W12 cell line in which all the phases of carcinogenesis take place 
during passages, including integration and E2 regulation loss, was utlised. RT-PCR, western-blot and 
immunoprecipitation were employed  to detect viral and cellular expression at early  (W12E) and late passages (W12G).  
The EGFR expresssion was very high in W12G, and its expression correlated with disease progression. The highest 
difference was seen in the expression of ErbB3 and ErbB 4 receptors with a reduction from the early to the  late 
passages of W12. These data suggest that the expression of ErbB family is finely tuned with a clear inhibition of the 
ErbB 4 expression  during transformation. Since  the expression of this receptor is limited to a less aggressive 
behaviour, its expression could be useful as favourable prognostic marker. 
 
20 
Effect of the expression of influenza A virus NS1 protein in human and avian cell lines. 
Carli I, Tibaldi E1, Sartori E, Calistri A, Del Vecchio C, Palù G, 1Brunati A and C. Parolin2 
Department of Histology, Microbiology and Medical Biotechnologies, 1Department of Biochemestry, 2Department of 
Biology, University of Padova Italy 
The NS1 protein of influenza A virus is a 24 kDa multifunctional protein that plays a key role during infection by 
counteracting cellular antiviral activities and now is recognizes as pathogenicity factor of the virus. Recently it has been 
demonstrated that NS1 protein exists in different forms distinguished in the carboxy terminal region’s length. These 
variants can be generated by the introduction of a premature stop codon in the ns1 gene that in turns produces truncated 
protein’s variants. We have focused our work on three forms of NS1 protein, identified in a screening of 40 avian 
influenza isolates (subtype H7N1 and H7N3) circulating in Italy between 1999 and 2003: a full-length form, of 230 aa, 
and two truncated forms, of 224 aa and 220 aa. Interestingly, all and only the viruses classified as high pathogenic 
express the intermediate form (224aa) of NS1 protein. We want to identify cellular specific partner of interaction of the 
three forms of  NS1 protein and, in case, to determine the involvement of specific kinase that may explain the different 
outcome of viral infection. For this we optimize the method of expression of the three forms of the viral protein in 
human and avian cell lines and we want to identify specific cellular partners by co-immunoprecipitation and mass 
spectrometry. Moreover we intend to perform kinase activity assay to analyze the capacity of NS1 protein to interfere 
with specific cellular pathway and then to promote viral replication and pathogenicity. 
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New immunogens for the induction of broad spectrum neutralizing antibodies against human 
immunodeficiency virus type 1 (HIV-1). 
Dalila Astone, Paola Rossolillo, Andrea Matucci, Pierpaolo Racchiolli, Alessandra Ruggiero, Donato Zipeto 
Section of Biology and Genetics, DMIBG, University of Verona, Verona, Italy 
 
INTRODUCTION: Broad spectrum neutralizing antibodies against HIV-1 are considered a central point for the 
development of an AIDS vaccine. Conserved epitopes which are transiently exposed during the fusion process between 
viral envelope and target cell, might also be present on CD4-independent gp120/41. Fusion complex intermediates and 
CD4-independent gp120/41s represent new immunogens that could induce broad spectrum neutralizing antibodies. 
METHODS: We immunized mice with fusion complexes, showing the induction of broad spectrum neutralizing 
antibodies. We prepared murine hybridomas and screened for neutralizing activity of secreted antibodies. We 
immunized mice and rabbits with CD4-independent HIV-1 envelope glycoproteins to evaluate their immunogenicity.  
RESULTS: Fusion complexes were immunogenic and induced antibodies with neutralizing activity against 
heterologous HIV-1 isolates. 8% of hybridoma antibodies showed a neutralizing activity higher than 40%, and 2% had 
an activity higher than 70%.  This was specific for HIV-1 and was not due to the presence of receptor-coreceptor 
antibodies. Hybridoma supernatants containing antibodies with the highest and broadest neutralizing activity are being 
tested for further characterization. Sera from mice and rabbits immunized with CD4-independent gp120/41s were able 
to neutralize the infectivity of heterologous HIV-1 isolates in the presence of soluble CD4. DISCUSSION: The 
induction of broad spectrum neutralizing antibodies against HIV-1, using fusion complexes and CD4-independent 
gp120/41s, represents an important step toward the development of a vaccine against HIV-1/AIDS. 
 
 
 
 
 
 
 
 
 
48 
Construction and characterization of recombinant fowlpox viruses expressing human papilloma 
virus E6 and E7 oncoproteins. 
Carlo Zanottoa, Eleana Pozzia, Sole Pacchionia, Luca Volontéa, Carlo De Giuli Morghena,c, and Antonia Radaellib,c, 
a Department of Medical Pharmacology, University of Milan, 20129 Milan, Italy 
b Department of Pharmacological Sciences, University of Milan, 20133 Milan, Italy 
c Cellular and Molecular Pharmacology Section, Institute of Neurosciences, University of Milan, 20129 Milan, Italy 
 
Human papilloma virus (HPV)-16 is the most prevalent high-risk mucosal genotype and the expression of the E6 and E7 
proteins, which can bind the p53 and p105Rb host cell-cycle regulatory proteins, is related to its tumorigenicity. Virus-like-
particle (VLP)-based immunogens developed recently have proven to be successful as prophylactic HPV vaccines. 
However, given the high number of individuals already infected with HPV and the absence of expression of the L1 
structural protein in HPV-infected or HPV-transformed cells, an efficient therapeutic vaccine targeting the non-structural E6 
and E7 oncoproteins is required.  
In this study, two new fowlpox virus (FPV) recombinants encoding the HPV-16 E6 and E7 proteins were engineered and 
evaluated for their correct expression in vitro, with the final aim of developing a therapeutic vaccine against HPV-related 
cervical tumors.  
Although vaccinia viruses expressing the HPV-16 and HPV-18 E6 and E7 oncoproteins have already been studied, due to 
their natural host-range restriction to avian species and their ability to elicit a complete immune response, FPV recombinants 
may represent efficient and safer vectors also for immunocompromised hosts.  
The results indicate that FPV recombinants can express correctly the E6 and E7 oncoproteins, and they should represent 
appropriate vectors for their expression in human cells. After genetically modifying the E6 and E7 oncogenes to avoid their 
binding to p53 and p105Rb cellular substrates, and after evaluating their innocuity and immunogenicity, these avipox-based 
putative vaccines can be examined for specific elimination of HPV-positive tumor cells. 
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Fusion Complexes and CD4-
Independent Env for the Induction 
of Broad Spectrum Neutralizing 
Antibodies Against HIV-1
Dalila Astone, Paola Rossolillo, Andrea Matucci, 
Pierpaolo Racchiolli, Andrea Cara* and Donato 
Zipeto
Laboratory of Molecular Virology, Section of Biology and 
Genetics, Department of Life and Reproduction Sciences, 
University of Verona, Verona, Italy, and *Department of 
Therapeutic Research and Medicines Evaluation, Istituto 
Superiore di Sanità, Rome, Italy
Introduction:  Broad spectrum neutralizing antibodies 
against HIV-1 are essential for the development of a humoral 
anti-AIDS vaccine. We used fusion complexes and CD4-inde-
pendent gp120 as new immunogens to induce neutralizing 
antibodies blocking the infectivity of different primary iso-
lates of HIV-1.
Methods:  Spleen cells from mice immunized with fusion 
complexes were used to prepare murine hybridomas. Secreted 
antibodies were screened for their neutralizing activity using 
the pseudovirus standard neutralization assay. In parallel, the 
immunogenicity of CD4-independent Env, on which con-
served epitopes might be exposed, has been tested.
Results:  Among antibodies secreted by hybridoma clones, 
8% showed a neutralizing activity higher than 40% (1 !g/ml), 
and the best ones showed neutralization levels as high as 
80% against the pseudovirus B panel, reaching neutraliza-
tion levels similar or higher than the Tri-mAb control. 10 
hybridoma clones showing 80% or higher neutralization lev-
els were selected and re-cloned by limiting dilutions. Panel C 
evaluation is ongoing. Preliminary results using a 1:1000 sera 
dilution from mice immunized with CD4-independent Env 
showed a neutralizing activity of 40-60% and, as expected, a 
2-3 folds neutralization increase in the presence of sCD4.
Conclusions: Monoclonal antibodies obtained by immuniz-
ing with fusion complexes showed a broad spectrum neutral-
izing activity against all panel B pseudoviruses, as well as 
against a group of selected laboratory isolates.  Sera from 
mice immunized with CD4-independent Env showed neutral-
izing activity against heterologous Envs that increases in the 
presence of sCD4, suggesting the elicitation of antibodies 
against the conserved coreceptor binding site. In conclusion, 
fusion complexes and CD4-independent Env represent poten-
tial new immunogens that can induce neutralizing antibodies 
with activity against a wide panel of HIV-1 isolates.
157a
HLA-C Associates with Env and 
Increases HIV-1 Infectivity
Marco Turci, Pierpaolo Racchiolli, Serena Ziglio, 
Dalila Astone, Almudena Blanco and Donato 
Zipeto
Laboratory of Molecular Virology, Section of Biology and 
Genetics, Department of Life and Reproduction Sciences, 
University of Verona, Verona, Italy
Introduction:  Host cell proteins are specifically incorpo-
rated into HIV-1 envelope during budding. Virionic HLA-
C reduces HIV-1 susceptibility to neutralizing antibodies 
(Cosma 1999). A polymorphism in the 5’ region of the HLA-
C gene has been associated to individual variations in set 
point viral loads (Fellay 2007), suggesting a role of HLA-C 
expression levels in modulating HIV-1 infectivity. We have 
reported (Matucci 2008; Baroni 2010) that HLA-C in the 
HIV-1 envelope associates to Env increasing viral infectivity 
of both R5 and X4 tropic viruses.  The purpose of this study 
is to elucidate this interaction and exploit it for generating 
new immunogens capable of conferring protective immunity.
Methods:  Using recombinant HLA-C and Env molecules 
fused to fluorescent tags, we are studying their associa-
tion using the bimolecular fluorescence complementation 
(BiFC) technique. BiFC allows the analysis of the interac-
tion between associated proteins in living cells and to study 
their co-localization into cellular compartments. Env-deletion 
mutants and Env swapped domain recombinants are being 
tested to identify protein domains involved in their associa-
tion. HLA-C coded by different alleles will be analyzed for 
their association with Env to study the influence of HLA-C 
polymorphisms in increasing HIV-1 infectivity.
Results:  Preliminary results on Env-HLA-C associa-
tion and sub-cellular compartmentalization, using a specific 
marker for ER, reveal a direct proximity between these 
proteins, suggesting an early association at the ER level. 
Similarly, analysis of co-localization between Golgi apparatus 
and Env-HLA-C reveal the presence of the complementation 
signal between the two proteins in Golgi vesicles.
Conclusions:  BiFC assays allows an efficient visualiza-
tion of HLA-C and HIV-1 Env association in living cells. 
Preliminary results obtained suggest an association between 
the two proteins at the ER and Golgi level.  Understanding 
the interaction between HLA-C and HIV-1 Env might give 
valuable information for the design of new immunogens and/
or compounds that, by reducing viral infectivity, may help 
controlling HIV-1 infection.
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Post-entry events of efficient R5 vs. inefficient 
X4 HIV-1 replication in primary CD4+ T 
lymphocytes, a transcriptome analysis 
 
Samanta A. Mariani1, Andrea Crotti1, Elisa 
Vicenzi1, Huang Dawei 2, Richard Lempicky2, 
Claudia Cicala3, James Arthos3 & Guido Poli1  
1Department of Immunology, Transplantation and 
Infectious Diseases, San Raffaele Scientific 
Institute, Milan, Italy; 2Science Applications 
International Corporation, Frederick, MD USA; 
3National Institute of Allergy and Infectious 
Diseases, Bethesda, MD USA 
 
HIV-1 infects CD4+ cells via interaction with CD4 
and either CCR5 or CXCR4. However, only CCR5-
using (R5) viruses are efficiently transmitted and 
sustain the viral pandemics, while CXCR4-using 
(X4) viruses emerge later in coincidence with the 
immunodeficiency state and progression to AIDS in 
about 50% of individuals infected with subtype B 
HIV-1, but not with other subtypes. Unravelling 
cellular and molecular correlates of this asymmetric 
co-receptor use would be relevant to understand 
HIV pathogenesis as well as for the development of 
preventive strategies aimed at blocking R5 HIV-1 
spreading. We have previously reported that cord 
blood derived CD4+ T cells (CB4 cells) maintained 
in a sub-optimally activated state in IL-2 enriched 
medium for 7-14 days before infection are 
permissive for R5 and restricted for X4 HIV-1 
replication. Of interest, this restriction did not occur 
at the level of viral entry, but it was rather 
correlated to a superior capacity of R5 HIV-1 to 
spread after infection [Vicenzi E et al., 1999]. In the 
present study, we examined the transcriptomic 
profile at different time points (8, 24, 48, 72 h) of 
CB4 cells established from 6 independent 
donor/infection pairs after infection with isogenic 
NL4-3 (X4) and NL-AD8 (R5) viruses normalized 
for MOI. Gene expression was measured using 
Human Genome U95A chips and analyzed with the 
DAVID knowledge base software. Approximately 
900 and 1,100 genes were selectively mobilized by 
R5 and X4 HIV-1 infection, respectively, vs. mock-
stimulated uninfected control cells. An additional 
420 genes were modulated by both viruses vs. 
controls. R5 HIV-1 induced a rapid mobilization of 
genes linked to cell proliferation and signal 
transduction, whereas the X4 virus predominantly 
modulated the expression of genes associated with 
cell death and the immune response. Both viruses 
upregulated the expression of CXCL12/SDF-1?, 
but only X4 downregulated CXCR4 mRNA; CCR5 
mRNA was unaffected by either infection at all 
time points. Other genes previously linked to 
control of HIV replication that were modulated by 
R5 and X4 HIV-1 include APOBEC-3G, IFN-?, 
CCL5/RANTES, CCL7/MCP-3 and CCL14/HCC1. 
We are currently analyzing additional genes 
discordantly co-modulated by R5 and X4 viruses in 
the search of host genes associated with the 
permissive vs. restricted HIV replicative profile in 
this model system. Thus, both R5 and X4 HIV-1 
profoundly affect the transcriptional activity of 
primary CD4+ T lymphocytes even in the absence 
of overt replication (as observed in X4 infection). 
 
 
HLA-C increases HIV-1 infectivity by 
interacting with the envelope glycoprotein gp120 
 
Almudena Blanco, Serena Ziglio, Pierpaolo 
Racchiolli, Dalila Astone, Marco Turci, Donato 
Zipeto 
Laboratory of Molecular Virology, Section of 
Biology and Genetics, Department of Life and 
Reproduction Sciences, University of Verona, Italy 
 
Introduction: Host cell proteins are specifically 
incorporated into HIV-1 envelope during budding. 
It has been reported that virionic HLA-C reduces 
HIV-1 susceptibility to neutralizing antibodies 
(Cosma et al., 1999). A polymorphism in the 5’ 
region of the HLA-C gene has been associated to 
individual variation in set point viral loads (Fellay 
et al., 2007), suggesting a role of HLA-C 
expression levels in modulating HIV-1 infection. 
We have recently reported that HLA-C present in 
HIV-1 envelope associates to the viral envelope 
glycoprotein gp120 increasing viral infectivity of 
both R5 and X4 tropic viruses (Matucci et al., 2008; 
Baroni et al., 2010). 
The purpose of our study is to elucidate this 
interaction and exploit it for generating new 
immunogens capable of conferring protective 
immunity. 
Methods: Using recombinant HLA-C and Env 
molecules fused to fluorescent tags, we are studying 
their association using the bimolecular fluorescence 
complementation (BiFC) technique. BiFC allows 
the analysis of the interaction between associated 
proteins in living cells and to study their co-
localization into cellular compartments. Env-
deletion mutants and Env swapped domain 
recombinants are being constructed and tested to 
identify protein domains involved in their 
association. HLA-C coded by different alleles are 
being analyzed for their association with Env to 
study the influence of HLA-C polymorphisms in 
increasing HIV-1 infectivity. 
Results: Preliminary results on Env-HLA-C 
association and sub-cellular compartmentalisation, 
using a specific marker for the endoplasmic 
reticulum (ER), reveal a direct proximity between 
the two proteins, suggesting an early association at 
the ER level. Similarly, the analysis of the co-
localization between Golgi apparatus and Env-
HLA-C complex reveals the presence of the 
complementation signal between the two proteins in 
Golgi vesicles. 
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